<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="epi412934" xml:lang="en" article-type="review-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Epilepsia Open</journal-id><journal-id journal-id-type="iso-abbrev">Epilepsia Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2470-9239</journal-id><journal-id journal-id-type="publisher-id">EPI4</journal-id><journal-title-group><journal-title>Epilepsia Open</journal-title></journal-title-group><issn pub-type="epub">2470-9239</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38560778</article-id><article-id pub-id-type="pmc">11145612</article-id>
<article-id pub-id-type="doi">10.1002/epi4.12934</article-id><article-id pub-id-type="publisher-id">EPI412934</article-id><article-id pub-id-type="other">EPI4-0086-2023.R3</article-id><article-categories><subj-group subj-group-type="overline"><subject>Narrative Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Narrative Review</subject></subj-group></article-categories><title-group><article-title>Potassium channel&#x2010;related epilepsy: Pathogenesis and clinical features</article-title><alt-title alt-title-type="left-running-head">Zhao <sc>et&#xA0;al.</sc>
</alt-title></title-group><contrib-group><contrib id="epi412934-cr-0001" contrib-type="author"><name><surname>Zhao</surname><given-names>Tong</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6593-7134</contrib-id><xref rid="epi412934-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="epi412934-cr-0002" contrib-type="author"><name><surname>Wang</surname><given-names>Le</given-names></name><xref rid="epi412934-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="epi412934-cr-0003" contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Fang</given-names></name><xref rid="epi412934-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>17736908199@163.com</email></address></contrib></contrib-group><aff id="epi412934-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Hebei Children's Hospital</institution>
<city>Shijiazhuang</city>
<named-content content-type="country-part">Hebei</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Fang Chen, Hebei Children's Hospital, Shijiazhuang 050031, Hebei Province, China.<break/>
Email: <email>17736908199@163.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><volume>9</volume><issue seq="50">3</issue><issue-id pub-id-type="doi">10.1002/epi4.v9.3</issue-id><fpage>891</fpage><lpage>905</lpage><history>
<date date-type="rev-recd"><day>11</day><month>3</month><year>2024</year></date>
<date date-type="received"><day>25</day><month>4</month><year>2023</year></date>
<date date-type="accepted"><day>17</day><month>3</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2024 International League Against Epilepsy--><copyright-statement content-type="article-copyright">&#xA9; 2024 The Authors. <italic toggle="yes">Epilepsia Open</italic> published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x2010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:EPI4-9-891.pdf"/><abstract><title>Abstract</title><p>Variants in potassium channel&#x2010;related genes are one of the most important mechanisms underlying abnormal neuronal excitation and disturbances in the cellular resting membrane potential. These variants can cause different forms of epilepsy, which can seriously affect the physical and mental health of patients, especially those with refractory epilepsy or status epilepticus, which are common among pediatric patients and are potentially life&#x2010;threatening. Variants in potassium ion channel&#x2010;related genes have been reported in few studies; however, to our knowledge, no systematic review has been published. This study aimed to summarize the epilepsy phenotypes, functional studies, and pharmacological advances associated with different potassium channel gene variants to assist clinical practitioners and drug development teams to develop evidence&#x2010;based medicine and guide research strategies. PubMed and Google Scholar were searched for relevant literature on potassium channel&#x2010;related epilepsy reported in the past 5&#x2013;10&#x2009;years. Various common potassium ion channel gene variants can lead to heterogeneous epilepsy phenotypes, and functional effects can result from gene deletions and compound effects. Administration of select anti&#x2010;seizure medications is the primary treatment for this type of epilepsy. Most patients are refractory to anti&#x2010;seizure medications, and some novel anti&#x2010;seizure medications have been found to improve seizures. Use of targeted drugs to correct aberrant channel function based on the type of potassium channel gene variant can be used as an evidence&#x2010;based pathway to achieve precise and individualized treatment for children with epilepsy.</p><sec id="epi412934-sec-0002"><title>Plain Language Summary</title><p>In this article, the pathogenesis and clinical characteristics of epilepsy caused by different types of potassium channel gene variants are reviewed in the light of the latest research literature at home and abroad, with the expectation of providing a certain theoretical basis for the diagnosis and treatment of children with this type of disease.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="epi412934-kwd-0001">epilepsy</kwd><kwd id="epi412934-kwd-0002">functional studies</kwd><kwd id="epi412934-kwd-0003">genes</kwd><kwd id="epi412934-kwd-0004">potassium channels</kwd><kwd id="epi412934-kwd-0005">therapy</kwd></kwd-group><counts><fig-count count="1"/><table-count count="9"/><page-count count="15"/><word-count count="7874"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.4 mode:remove_FC converted:03.06.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="EPI412934-cit-2001">
<string-name>
<surname>Zhao</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>F</given-names>
</string-name>. <article-title>Potassium channel&#x2010;related epilepsy: Pathogenesis and clinical features</article-title>. <source>Epilepsia Open</source>. <year>2024</year>;<volume>9</volume>:<fpage>891</fpage>&#x2013;<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1002/epi4.12934</pub-id>
</mixed-citation>
</p></notes></front>
  <body id="epi412934-body-0001">
    <p>
<boxed-text position="anchor" content-type="box" id="epi412934-blkfxd-0001"><caption><title>Key points</title></caption><p>
<list list-type="bullet" id="epi412934-list-0001"><list-item id="epi412934-li-0001"><p>Potassium channels are ion channels that selectively allow the passage of potassium ions by a relatively complex mechanism. They are widely expressed in systems throughout the body, maintain neuronal membrane potential, regulate excitability, and participate in the repolarization process of neurons, which is closely associated with the development of neurological diseases.</p></list-item><list-item id="epi412934-li-0002"><p>Potassium channel isoforms associated with epilepsy pathogenesis include KCa, KNa and Kv, which are encoded by a variety of genes, mainly <italic toggle="yes">KCNA1</italic>, <italic toggle="yes">KCNA2</italic>, <italic toggle="yes">KCNB1</italic>, <italic toggle="yes">KCNC1</italic>, <italic toggle="yes">KCNH1</italic>, <italic toggle="yes">KCNQ2</italic>, <italic toggle="yes">KCNQ3</italic>, <italic toggle="yes">KCNT1</italic>, <italic toggle="yes">KCNT2</italic>, <italic toggle="yes">KCNT1</italic> and <italic toggle="yes">KCNMA1</italic>.</p></list-item><list-item id="epi412934-li-0003"><p>Genetic and de novo variants in potassium channel genes can lead to alterations in the structural function or expression of potassium channels, triggering abnormal neuronal discharges leading to different forms of epileptogenesis.</p></list-item><list-item id="epi412934-li-0004"><p>The severity of epilepsy due to variants in potassium channel genes is closely related to the type of channel dysfunction and changes at the cellular molecular level due to the genetic variant, and understanding the pathogenesis of the variant such as alterations in channel function will provide new ideas for the precise treatment of epilepsy.</p></list-item></list>
</p></boxed-text>
</p>
    <sec id="epi412934-sec-0005">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>Epilepsy is a neurological disorder caused by abnormal neuronal discharges in the brain.<xref rid="epi412934-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> There are million cases of epilepsy worldwide,<xref rid="epi412934-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> it is estimated that 70%&#x2013;80% of these cases are genetically inherited.<xref rid="epi412934-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> With the advancement in sequencing and diagnostic technologies in recent years,<xref rid="epi412934-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> an increasing number of epilepsy&#x2010;associated variants has been identified. Clinicians carrying out precision treatments based on genetic diagnosis results have been reported, which have revealed that variants of ion channel&#x2010;associated gene, including potassium ion channels, sodium ion channels, and others, account for 25% of inherited epilepsies.<xref rid="epi412934-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Detailed studies on the relationship between functional type and response to drug therapy in patients with epilepsy caused by genetic factors have yielded promising results for targeted drug therapy.<xref rid="epi412934-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="epi412934-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p>
      <p>Potassium channels play a crucial role in regulating neuronal excitability and are directly involved in seizure mechanisms.<xref rid="epi412934-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Potassium channels are distributed on the surface of all living cells and are involved in the generation of cellular action potentials and signal transduction.<xref rid="epi412934-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> They are classified according to the different combinations of &#x3B1;&#x2010; and &#x3B2;&#x2010;subunits and the presence of heterodimers in the inward rectifier potassium channel, Ca<sup>2+</sup>&#x2010;activated potassium channel (KCa), Na<sup>2+</sup>&#x2010;activated potassium channel (KNa), and voltage&#x2010;gated potassium channel (Kv).<xref rid="epi412934-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Variants in genes encoding potassium channels cause structural and functional changes in potassium channels, which can lead to epilepsy, seizure ataxia, and other disorders.<xref rid="epi412934-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p>
      <p>To our knowledge, till date, no systematic review has focused on variants in potassium ion channel&#x2010;related genes. Hence, we aimed to summarize the different types and phenotypes of epilepsy caused by variants in common potassium channel&#x2010;related genes, especially focusing on the effectiveness of drug treatment. Our findings may provide evidence&#x2010;based guidance for the drug&#x2010;based treatment of potassium channel&#x2010;associated epilepsy.</p>
    </sec>
    <sec id="epi412934-sec-0006">
      <label>2</label>
      <title>K<sub>V</sub> CHANNEL&#x2010;RELATED GENES AND EPILEPSY</title>
      <sec id="epi412934-sec-0007">
        <label>2.1</label>
        <title>Potassium voltage&#x2010;Gated channel subfamily A member 1 (<italic toggle="no">KCNA1</italic>)&#x2010;related epilepsy</title>
        <p>Variants in the <italic toggle="yes">KCNA1</italic> gene, which encodes Kv1.1, can cause a variety of neurologic disorders, including Episodic ataxia type 1 (EA1), epilepsy, epileptic encephalopathy (EE), and hypomagnesemia and rare paroxysmal dyskinesia disorders.<xref rid="epi412934-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Among these, EA1 is the only disorder solely associated with variants in the <italic toggle="yes">KCNA1</italic> gene. EA1 is the primary disorder caused by variants in the <italic toggle="yes">KCNA1</italic> gene. More than half of the known <italic toggle="yes">KCNA1</italic> variants only manifest in EA1, and the age of onset is often &lt;20&#x2009;years. Seizure symptoms include ataxia, myasthenia, dysarthria,<xref rid="epi412934-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="epi412934-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> vertigo,<xref rid="epi412934-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="epi412934-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> fever, exercise intolerance, mood changes, and fatigue,<xref rid="epi412934-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="epi412934-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> with or without epilepsy and EE. Electrophysiologic studies have found that loss&#x2010;of&#x2010;function (LOF) variants in <italic toggle="yes">KCNA1</italic> leads to EA1.<xref rid="epi412934-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="epi412934-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Acetazolamide (ACZ), phenytoin sodium (PHT), carbamazepine (CBZ), and lamotrigine (LTG) are drugs that could control seizures.<xref rid="epi412934-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="epi412934-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="epi412934-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p>
        <p>Both gain&#x2010;of&#x2010;function (GOF) and LOF variants in <italic toggle="yes">KCNA1</italic> can lead to epilepsy and EE. GOF variants are usually associated with drug&#x2010;sensitive epilepsy without neurodevelopmental disorder, whereas LOF variants generally trigger EE, with the majority of variant sites in patients being located in the highly conserved region of Kv1.1.<xref rid="epi412934-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> EE caused by <italic toggle="yes">KCNA1</italic> variants usually presents with early onset seizures and progressively manifests as cognitive, behavioral, and language deficits. Pro&#x2010;Val&#x2010;Pro motif variants<xref rid="epi412934-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> and copy number variants in <italic toggle="yes">KCNA1</italic> are likely to cause EE, and LOF variants in the gene can cause mental retardation and even sudden unexpected death in epilepsy.<xref rid="epi412934-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> While EE associated with variants in <italic toggle="yes">KCNA1</italic> is usually refractory to treatment with medications, a case of drug&#x2010;resistant epilepsy in a patient with a GOF variant in <italic toggle="yes">KCNA1</italic> has been reported in recent years. Patients whose seizures were somewhat controlled after the use of 4&#x2010;aminopyridine (4&#x2010;AP) have been reported.<xref rid="epi412934-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Verdura et&#xA0;al. found that oxcarbazepine (OXC) was effective in controlling seizures in a neonatal patient with EE with a LOF variant.<xref rid="epi412934-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p>
      </sec>
      <sec id="epi412934-sec-0008">
        <label>2.2</label>
        <title>Potassium voltage&#x2010;gated channel subfamily A member 2 (<italic toggle="no">KCNA2</italic>)&#x2010;related epilepsy</title>
        <p>
<italic toggle="yes">KCNA2</italic> variants can result in a variety of epilepsy phenotypes ranging from early&#x2010;onset epileptic encephalopathy (EOEE) to mild epilepsy. The former is often combined with mental retardation and the latter with complex hereditary spastic paraplegia, both of which are episodic ataxia.<xref rid="epi412934-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The mild epileptic phenotype is predominant in infancy, with generalized and focal seizures in later life without mental retardation, and individuals with this variant usually have a mixed dysfunction.<xref rid="epi412934-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> EOEE is a group of epilepsies in which there is severe phenotypic and genetic heterogeneity, with seizures appearing at approximately 5&#x2013;17&#x2009;months of age. Patients subsequently exhibit global developmental delay or even developmental neurodevelopmental regression.<xref rid="epi412934-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Syrbe et&#xA0;al. reported six patients with <italic toggle="yes">KCNA2</italic>&#x2010;associated EOEE, four of whom had a nearly complete loss of channel function, and two of whom had GOF variants.<xref rid="epi412934-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> A child with EOEE and mild epilepsy was found to have mixed dysfunction on diaphragm clamp testing.<xref rid="epi412934-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Masnada et&#xA0;al. reported that, among 10 patients with EE with <italic toggle="yes">KCNA2</italic> gene variants, three patients with LOF variants had mild symptoms, mostly focal seizures, which could be accompanied with speech and cognitive delay; four patients with GOF variants had ataxia as the main clinical manifestation, and the epilepsy type was often generalized seizures, and cognitive deficits were more severe than those of patients with LOF variants; and the three patients with mixed dysfunction had the earliest onset of epilepsy and the most severe symptoms.<xref rid="epi412934-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Currently, 4&#x2010;AP is mostly used for <italic toggle="yes">KCNA2</italic>&#x2010;related EOEE, in which more than 80% of the children have positive treatment outcomes.<xref rid="epi412934-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="epi412934-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> ACZ has been found to be effective in controlling seizures of this phenotype.<xref rid="epi412934-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Seizures of this phenotype have also been controlled using valproate sodium (VPA) in combination with ethosuximide.<xref rid="epi412934-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p>
        <p>In addition to epilepsy, <italic toggle="yes">KCNA2</italic> variants have been identified in other diseases in recent years. Canafoglia et&#xA0;al. reported one male patient carrying a <italic toggle="yes">KCNA2</italic> GOF variant who presented with only progressive myoclonus epilepsy (PME).<xref rid="epi412934-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Manole et&#xA0;al. reported a patient with a <italic toggle="yes">KCNA2</italic> LOF variant who presented with only hereditary spastic paraplegia, mild ataxia, and dysarthria.<xref rid="epi412934-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Neither of the two cases exhibited an epileptic phenotype, and a observational clinical study on the cases extends the disease phenotypes associated with this gene, thereby suggesting genotypic heterogeneity.<xref rid="epi412934-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="epi412934-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p>
      </sec>
      <sec id="epi412934-sec-0009">
        <label>2.3</label>
        <title>Potassium voltage&#x2010;gated channel subfamily B member 1 (<italic toggle="no">KCNB1</italic>)&#x2010;related epilepsy</title>
        <p>The <italic toggle="yes">KCNB1</italic> gene encodes Kv2.1, which is the main channel for delayed rectifier potassium currents in hippocampal and cortical vertebral neurons.<xref rid="epi412934-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Functional studies by Torkamani et&#xA0;al. have shown that <italic toggle="yes">KCNB1</italic> gene variants have been found as a GOF effect in EE phenotypes.<xref rid="epi412934-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Saitsu et&#xA0;al. reported a child with EE caused by a <italic toggle="yes">KCNB1</italic> gene variant who was sensitive to the sodium channel blocker peptide guangxitoxin&#x2010;1 (GxTX)<xref rid="epi412934-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> and found that at the cellular level GxTX was effective in blocking Kv2.1&#x2010;mediated currents.<xref rid="epi412934-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> Recently, a full LOF&#x2010;effect <italic toggle="yes">KCNB1</italic> variant was also found in a patient with EOEE with disease onset occurring in infancy.<xref rid="epi412934-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> The gene variant was found in a patient with a moderate EE phenotype, who presented with autism, epilepsy, and mental retardation, which was found to be a partial LOF upon functional analysis that responded well to the administration of the antiepileptic therapy sulthiame.<xref rid="epi412934-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Bar et&#xA0;al. reviewed 27 patients with <italic toggle="yes">KCNB1</italic> variants and found that, among them, most of the patients with the severe phenotype had missense variants located on the pore domains of the potassium channels, whereas most of the patients with the moderate epilepsy phenotype had truncating variants that were located on the C&#x2010;terminal structural domains.<xref rid="epi412934-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Xiong et&#xA0;al. similarly found that mild epilepsy phenotypes were caused by truncating variants.<xref rid="epi412934-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Kovel et&#xA0;al. proposed that variants in the N&#x2010;terminal structural domain are lethal.<xref rid="epi412934-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> This hypothesis has been proven in patients with mild epilepsy.</p>
        <p>Two children with epilepsy carrying nonsense <italic toggle="yes">KCNB1</italic> variants with variant sites in the pore region and C&#x2010;terminal structural domains with mild phenotypes have been reported by Marini et&#xA0;al.<xref rid="epi412934-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Adrenocorticotropic hormone administration rapidly relieved the epileptic symptoms. Four children carrying missense variants had severe phenotypes; three of whom exhibited reduced seizure frequency but not complete control after a combination of medications, and medications were completely ineffective in one child.<xref rid="epi412934-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Notably, a child with epilepsy caused by a missense variant in <italic toggle="yes">KCNB1</italic>, for whom a combination of levetiracetam (LEV), OXC, VPA, and phenobarbital (PHB) had recently been ineffective, underwent a late ketogenic diet that was effective in reducing seizure frequency.<xref rid="epi412934-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</p>
        <p>Hence, truncating variants and nonsense variants located in the C&#x2010;terminal structural domain have a mild drug&#x2010;sensitive phenotype, whereas individuals with variants in the N&#x2010;terminal structural domain have severe symptoms and require long&#x2010;term follow&#x2010;up. Notably, anti&#x2010;seizure medications (ASMs) are usually ineffective in treating individuals with <italic toggle="yes">KCNB1</italic> missense variants, and a ketogenic diet may be a potential therapeutic option.</p>
      </sec>
      <sec id="epi412934-sec-0010">
        <label>2.4</label>
        <title>Potassium voltage&#x2010;gated channel subfamily C member 1 (<italic toggle="no">KCNC1</italic>)&#x2010;related epilepsy</title>
        <p>
<italic toggle="yes">KCNC1</italic> encodes a highly conserved potassium channel subunit of the Kv3 subfamily of voltage&#x2010;gated tetrameric potassium channels. Variants in this gene can trigger PME, which is a unique epilepsy characterized by progressive neurological decline with recurrent seizures of ataxia and myoclonus.<xref rid="epi412934-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Nascimento et&#xA0;al. demonstrated that <italic toggle="yes">KCNC1</italic> LOF variants disrupt neuronal firing, alter neurotransmitter release, and induce neuronal death. Inhibitory GABA and cerebellar neurons are among the most affected neurons, with damage to the former associated with epileptogenesis and the latter leading to cerebellar ataxia.<xref rid="epi412934-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> Treatment of this group of patients with benzodiazepines (BZDs) has been shown to be effective.<xref rid="epi412934-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> LOF variants in this gene have also been found in patients with developmental and epileptic encephalopathy (DEE). These patients have exhibited varying degrees of therapeutic responses to VPA; in one case, the number of seizures was &lt;1 per 3&#x2009;months after vagus nerve stimulation.<xref rid="epi412934-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> In addition, variants in this gene have been reported in patients presenting with only mental retardation, malformations, and no seizures.<xref rid="epi412934-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>
</p>
      </sec>
      <sec id="epi412934-sec-0011">
        <label>2.5</label>
        <title>Potassium voltage&#x2010;gated channel subfamily H member 1 (<italic toggle="no">KCNH1</italic>)&#x2010;related epilepsy</title>
        <p>
<italic toggle="yes">KCNH1</italic> encodes a highly conserved protein of the EAG subfamily of voltage&#x2010;gated potassium channels and is associated with a variety of neurological disorders. Variants in this gene have been found in a variety of syndromes, including deformities of facial features, hypoplasia or regenerative disorders of the nails, abnormalities of the thumbs and bones, mental retardation, and epileptic seizures.<xref rid="epi412934-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="epi412934-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> The most common syndromes are Temple&#x2013;Baraitser Syndrome and Zimmermann&#x2013;Laband syndrome.<xref rid="epi412934-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="epi412934-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> The former is characterized by facial dysmorphisms, enlarged gingival size, hirsutism, absence/hypoplasia of the nails and terminal phalanges, mental retardation, and epilepsy<xref rid="epi412934-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>; the latter is characterized by multisystemic disorders, epilepsy, and thumb and big toe nail hypoplasia. Syndromes triggered by variants in this gene may be poorly characterized,<xref rid="epi412934-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> as in the case of one patient with no obvious gingival and nail features reported by Mucca et&#xA0;al.<xref rid="epi412934-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> Recent studies have found a significant overlap of symptoms between the two syndromes, and it is considered that the two are a continuum of disorders.<xref rid="epi412934-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> In addition to the aforementioned syndromes, the gene has recently been identified in deafness and nail dystrophy syndromes.<xref rid="epi412934-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
</p>
        <p>Variants in this gene can also lead to a range of epilepsy types from benign isolated epilepsy and febrile seizures (FS) to severe EE. de novo variants in this gene, which are usually associated with EE, cluster in the transmembrane structural domains of S4 and S6, whereas somatic mosaicism or germline variants can lead to either isolated epilepsy or FS.<xref rid="epi412934-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> Certain patients' epileptic symptoms can be completely controlled by medications, whereas treatment in certain patients requires a combination of multiple drugs.<xref rid="epi412934-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>
</p>
      </sec>
      <sec id="epi412934-sec-0012">
        <label>2.6</label>
        <title>Potassium voltage&#x2010;gated channel subfamily Q member 2 (<italic toggle="no">KCNQ2</italic>)&#x2010;related epilepsy</title>
        <p>Sixty to seventy percent of all cases of benign familial neonatal epilepsy (BFNE) is caused by variants in <italic toggle="yes">KCNQ2</italic>. BFNE is an autosomal dominant epilepsy with a favorable prognosis.<xref rid="epi412934-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Seizures usually occur on the 2nd&#x2013; 8th day of age and resolve after 16&#x2009;months. The disorder usually begins with tonic seizures followed by a series of autonomic and motor changes that may be unilateral or bilateral or symmetrical. Seizures are brief but can occur as frequently as 30 times per day and even evolve into status epilepticus, usually accompanied by apnea.<xref rid="epi412934-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="epi412934-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> Sodium channel blockers, such as CBZ, LTG, and OXC, have been found to control seizures in the majority of patients with BFNE.<xref rid="epi412934-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> The seizures may be more severe than those in BFNE.</p>
        <p>Recently, <italic toggle="yes">KCNQ2</italic> gene variants have been identified in severe phenotypes of EE and EOEE. Previous functional studies of epilepsy found that variants in this gene have predominantly been LOF variants, whereas Miceli et&#xA0;al. found one patient with severe EE caused by a <italic toggle="yes">KCNQ2</italic> GOF variant; this functional difference may be related to the severity of the epilepsy.<xref rid="epi412934-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Weckhuysen et&#xA0;al. reported that eight patients with EOEE presented with intractable epileptic tonic seizures in the first postnatal week, and the electroencephalograms showed multifocal epileptic activity with severe mental retardation and motor deficits. Seizures were frequent despite the administration of various ASMs. The age and type of seizures in this phenotype are similar to those in BFNE, but the seizures are highly treatment&#x2010;resistant.<xref rid="epi412934-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Weckhuysen et&#xA0;al. reported that six patients with EOEE had similar severe symptoms, but one of them responded favorably to retigabine and three responded to leung&#x2010;ho with LTG, topiramate (TPM), and zonisamide.<xref rid="epi412934-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> Yang et&#xA0;al. developed a Xenopus oocyte model based on three patients carrying variants in <italic toggle="yes">KCNQ2</italic>, which were LOF variants determined by cellular electrophysiologic studies, and these patients showed a 90% reduction in seizures upon administration of retigabine.<xref rid="epi412934-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> Recently, a novel AED, SF0034, was approved for use in the United States. Its therapeutic mechanism is similar to that of retigabine, and the efficacy of this drug is 5&#x2010;fold higher than that of retigabine; however, its side effects limit the clinical application of this drug.<xref rid="epi412934-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>
</p>
      </sec>
      <sec id="epi412934-sec-0013">
        <label>2.7</label>
        <title>Potassium voltage&#x2010;gated channel subfamily Q member 3 (<italic toggle="no">KCNQ3</italic>)&#x2010;related epilepsy</title>
        <p>Variations in <italic toggle="yes">KCNQ3</italic> can cause a variety of epilepsy phenotypes, ranging from BFNE and benign familial infantile epilepsy (BFIE) to EE, and also developmental disorders, such as mental retardation in isolation.<xref rid="epi412934-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> BFNE and BFIE are autosomal dominant disorders, but the rate of detection of <italic toggle="yes">KCNQ3</italic> variants is low due to incomplete penetrance, parental chimerism, and other factors.<xref rid="epi412934-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="epi412934-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>
<italic toggle="yes">KCNQ3</italic>&#x2010;associated BFNE starts 2&#x2013;8&#x2009;days after birth, and seizures are mostly in the form of tonicity; epilepsy resolves on its own between 1&#x2009;month and 1&#x2009;year of age, and development is usually normal.<xref rid="epi412934-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> However, mental retardation has also been reported.<xref rid="epi412934-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> The functional effect of BFNE caused by the <italic toggle="yes">KCNQ3</italic> gene variant is LOF, and the sodium channel blocker PHT is most commonly used in the treatment of this disease that yields favorable results.<xref rid="epi412934-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Tulloch et&#xA0;al. reported that patients with BFNE respond well to LEV therapy.<xref rid="epi412934-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> CBZ and OXC were also effective in controlling seizures, and CBZ was found to have no side effects with its best effects being exerted the earlier it was used.<xref rid="epi412934-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> Thus, BFNE caused by <italic toggle="yes">KCNQ3</italic> variant is generally effectively controlled by antiepileptic therapy.</p>
        <p>
<italic toggle="yes">KCNQ3</italic>&#x2010;associated BFIE develops within 1&#x2009;year of age and resolves on its own after 1&#x2013;2&#x2009;years of age, with a mostly focal form of seizures, and development is also usually normal, with complete seizure control achieved with PHB, CBZ, or VPA.<xref rid="epi412934-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> Developmental deficits caused by <italic toggle="yes">KCNQ3</italic>, manifestations of which include EE with progressive cognitive and neuropsychological worsening or deterioration, mental retardation without epilepsy, and seizures and cortical visual impairment with mental retardation, have functional effects that can be GOF or LOF.<xref rid="epi412934-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>, <xref rid="epi412934-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Sands et&#xA0;al. reported 11 patients presenting only with global developmental delay and autism with no epileptic manifestations and functional studies confirming <italic toggle="yes">KCNQ3</italic> variant as GOF.<xref rid="epi412934-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> EE and intellectual decline are GOF variants, and the use of retigabine eliminates the potassium channel electro&#x2010;mechanical (E&#x2010;M) caused by current disruption induced by <italic toggle="yes">KCNQ3</italic> variant, thus leading to antiepileptic therapeutic effects.<xref rid="epi412934-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> However, the drug is still contraindicated in children due to its skin and retinal discoloration side effects.</p>
      </sec>
    </sec>
    <sec id="epi412934-sec-0014">
      <label>3</label>
      <title>KNa&#x2009;+&#x2009;CHANNEL&#x2010;RELATED GENES AND EPILEPSY</title>
      <sec id="epi412934-sec-0015">
        <label>3.1</label>
        <title>Potassium sodium&#x2010;activated Channel subfamily T member 1 (<italic toggle="no">KCNT1</italic>)&#x2010;related epilepsy</title>
        <p>
<italic toggle="yes">KCNT1</italic> encodes a sodium&#x2010;activated potassium channel that is widely expressed in the nervous system and is primarily associated with two epileptic phenotypes, epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). EIMFS typically begins with focal seizures at 6&#x2009;months of age, and can progress to continuous seizures later in life, usually with developmental regression and autonomic nervous system manifestations.<xref rid="epi412934-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> Previously believed to be a GOF variant, Evely et&#xA0;al. recently reported a child with EIMFS, which was found to be caused by a LOF variant.<xref rid="epi412934-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> ADNFLE presents with nocturnal motor seizures ranging from simple arousals to those with tonic seizure or dystonia. Cognitive comorbidities, mental, and behavioral abnormalities can be observed at a young age, as well as complications, such as pulmonary hemorrhage, among others.<xref rid="epi412934-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>
</p>
        <p>Both of these phenotypes do not respond well to standard ASMs, and the sodium channel blocker quinidine was previously used to target the GOF effect in ElMFS but had little effect.<xref rid="epi412934-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> Recently, McTague et&#xA0;al. carried out a quinidine trial in one patient with EIMFS and two patients with ADNFLE, with one case of <italic toggle="yes">KCNT1</italic> GOF EIMFS responding favorably, and the remaining two failing respond.<xref rid="epi412934-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> The results of this trial are summarized in Table&#xA0;<xref rid="epi412934-tbl-0007" ref-type="table">7</xref>. A quinidine study on more than 20 children with <italic toggle="yes">KCNT1</italic>&#x2010;associated EIMFS showed that few experienced transient seizure&#x2010;free episodes, and the number of seizures was reduced by half in 20% of the patients.<xref rid="epi412934-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> Recently, Poisson et&#xA0;al. performed a study on the responsiveness of a new drug, cannabidiol, in three patients with EIMFS, and one patient showed a significant reduction in seizure intensity with developmental progression.<xref rid="epi412934-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> Datta et&#xA0;al. found that PHB or potassium bromide (KBr) alone were effective in controlling the EIMFS phenotype, but the positive effects were only observed with high doses of PHB.<xref rid="epi412934-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> The ADNFLE phenotype was well tolerated with stiripentol (STP), BZDs, LEV, and a ketogenic diet but showed limited results.<xref rid="epi412934-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> A quinidine trial performed on six patients diagnosed with ADNFLE revealed that none of them responded to the treatment; however, they experienced systemic cardiac side effects.<xref rid="epi412934-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>
</p>
        <p>In addition to triggering the above epilepsy types, <italic toggle="yes">KCNT1</italic> variants can cause temporal lobe epilepsy,<xref rid="epi412934-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> sleep&#x2010;related hypermotor epilepsy,<xref rid="epi412934-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> and malignant migratory partial seizures of infancy.<xref rid="epi412934-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>
</p>
      </sec>
      <sec id="epi412934-sec-0016">
        <label>3.2</label>
        <title>Potassium sodium&#x2010;activated Channel subfamily T member 2 (<italic toggle="no">KCNT2</italic>)&#x2010;related epilepsy</title>
        <p>
<italic toggle="yes">KCNT2</italic> variants can lead to different epilepsy phenotypes. Among two patients with <italic toggle="yes">KCNT2</italic> GOF variants, one was diagnosed with EIMFS and other with Ohtahara syndrome followed by infantile spasms, both of which showed dysmorphic features.<xref rid="epi412934-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> Recently, Mao reported two patients with EIMFS caused by <italic toggle="yes">KCNT2</italic> variants, and using patch clamp electrophysiology, both were found to have reduced channel currents, which were considered to be caused by LOF variants.<xref rid="epi412934-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> This is in contrast to the previously reported cases of EIMFS primarily caused by <italic toggle="yes">KCNT1</italic> GOF variants. EIMFS patients are usually drug resistant, and PHB can be administered to control symptoms to a certain degree.<xref rid="epi412934-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>, <xref rid="epi412934-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref> Ambrosino et&#xA0;al. reported two patients with DEE caused by variants in this gene, one of whom achieved a significant clinical outcome after the use of quinidine; thus, they hypothesized that this individual's condition may be caused by a GOF variant.<xref rid="epi412934-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> The results of this study are summarized in Table&#xA0;<xref rid="epi412934-tbl-0008" ref-type="table">8</xref>. Notably, drug resistance is present in most <italic toggle="yes">KCNT2</italic>&#x2010;associated DEE phenotypes.<xref rid="epi412934-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>
</p>
        <p>The spectrum of disease phenotypes caused by <italic toggle="yes">KCNT2</italic> variants is increasing. Inuzuka et&#xA0;al. identified one new phenotype of frontal lobe epilepsy caused by variants in this gene, in which patients usually have frontal lobe seizures during sleep and present with refractory stereotypic and focal motor seizures.<xref rid="epi412934-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref> Jackson et&#xA0;al. reported that two patients with a p.Arg190 missense variant in <italic toggle="yes">KCNT2</italic> did not exhibit epilepsy and only presented with mental retardation and dysmorphic features.<xref rid="epi412934-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> Tian et&#xA0;al. identified <italic toggle="yes">KCNT2</italic> variants in a family with generalized epilepsy with febrile seizures plus.<xref rid="epi412934-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref>
</p>
      </sec>
    </sec>
    <sec id="epi412934-sec-0017">
      <label>4</label>
      <title>KCa<sup>+</sup> CHANNEL&#x2010;RELATED GENES AND EPILEPSY</title>
      <sec id="epi412934-sec-0018">
        <label>4.1</label>
        <title>Potassium Calcium&#x2010;activated channel subfamily M alpha 1 (<italic toggle="no">KCNMA1</italic>)&#x2010;related epilepsy</title>
        <p>The large&#x2010;conductance Ca<sup>2+</sup>&#x2010;activated K<sup>+</sup> channel, also known as the BK channel, differs from other K<sup>+</sup> channels in that it is activated by both intracellular Ca<sup>2+</sup> ions and membrane depolarization. The BK channel plays a role in regulating cell membrane excitability and calcium signaling, and the channel prevents epilepsy by preventing excess intracellular calcium ions from triggering neuronal hyperexcitability.<xref rid="epi412934-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> The channel is composed of four &#x3B1;&#x2010;subunits and four optional auxiliary &#x3B2;&#x2010;subunits. Of these, the pore&#x2010;forming &#x3B1;&#x2010;subunit is encoded by <italic toggle="yes">KCNMA1</italic>, which generates a variety of isoforms by alternative splicing.<xref rid="epi412934-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref>, <xref rid="epi412934-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> In addition to epilepsy, neurologic phenotypes of <italic toggle="yes">KCNMA1</italic>&#x2010;associated ion channelopathies include language and motor developmental delays, cerebellar atrophy, microcephaly, hypotonia, facial deformity, visceral malformation, and dyskinesia.<xref rid="epi412934-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref> In addition, <italic toggle="yes">KCNMA1</italic>&#x2010;associated ion channelopathies cause a number of neurologic disorders. Almost all patients with <italic toggle="yes">KCNMA1</italic>&#x2010;associated ion channelopathies present with paroxysmal non&#x2010;kinesigenic dyskinesia (PNKD), epilepsy, or both.<xref rid="epi412934-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>
</p>
        <p>Wang et&#xA0;al. found that the majority of patients with <italic toggle="yes">KCNMA1</italic> variants had paroxysmal dyskinesias with or without epilepsy, most with mental retardation, and drug resistance.<xref rid="epi412934-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref> Moldenhauer et&#xA0;al. found that <italic toggle="yes">KCNMA1</italic> variant resulting in dyskinesia combined with an epileptic phenotype was a GOF effect and that ACZ was largely ineffective, but paroxetine had a therapeutic effect.<xref rid="epi412934-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref> Keros et&#xA0;al. reported six PNKD patients who responded well to lisdexamfetamine, with a reduction in the number of seizures observed in all patients, ranging from a 10&#x2010;fold reduction to complete remission.<xref rid="epi412934-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> For <italic toggle="yes">KCNMA1</italic>&#x2010;associated epilepsy, <italic toggle="yes">KCNMA1</italic> variants that cause GOF or LOF of BK channel mechanisms have been found to be associated with seizures. Ninety&#x2010;four studies have demonstrated that the use of BK current potassium channel openers and blockers are effective in controlling epilepsy caused by this gene.<xref rid="epi412934-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref> To date, the role of BK channels in epilepsy remains controversial, and its function type requires further study with large sample sizes or modeling studies.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="epi412934-sec-0019">
      <label>5</label>
      <title>DISCUSSION</title>
      <p>Epilepsy phenotypes due to mutations in potassium channel genes range from mild to severe, but most phenotypes are developmental epileptic encephalopathies, which can be combined with disorders such as mental retardation, language developmental disorders, and autism. In&#x2010;depth investigation of the pathogenesis of mutants and animal models such as mice and tissues and cells has yielded changes in the channel currents of some mutant&#x2010;induced phenotypes (see Figure&#xA0;<xref rid="epi412934-fig-0001" ref-type="fig">1</xref> and Tables&#xA0;<xref rid="epi412934-tbl-0001" ref-type="table">1</xref>, <xref rid="epi412934-tbl-0002" ref-type="table">2</xref>, <xref rid="epi412934-tbl-0003" ref-type="table">3</xref>, <xref rid="epi412934-tbl-0004" ref-type="table">4</xref>, <xref rid="epi412934-tbl-0005" ref-type="table">5</xref>, <xref rid="epi412934-tbl-0006" ref-type="table">6</xref>, <xref rid="epi412934-tbl-0007" ref-type="table">7</xref>, <xref rid="epi412934-tbl-0008" ref-type="table">8</xref>, <xref rid="epi412934-tbl-0009" ref-type="table">9</xref>) as well as changes in some cell signaling molecules, and the use of drugs such as potassium or sodium channel blockers in function&#x2010;gaining mutants or animal models has yielded good results, while on the other hand, the loss&#x2010;of&#x2010;function has led to avoidance of the use of potassium channel blockers or the use of inhibitory neuropathogens in accordance with the changes in cell signaling. Cell signaling changes, drugs that promote excitation of inhibitory neurons are selected.</p>
      <fig position="float" fig-type="FIGURE" id="epi412934-fig-0001">
        <label>FIGURE 1</label>
        <caption>
          <p>Schematic diagram of the pathogenesis and channel function changes in epilepsy and epileptic syndromes due to variants in common potassium channel genes.</p>
        </caption>
        <graphic xlink:href="EPI4-9-891-g001" position="anchor" id="jats-graphic-1"/>
      </fig>
      <table-wrap position="float" id="epi412934-tbl-0001" content-type="TABLE">
        <label>TABLE 1</label>
        <caption>
          <p>Clinical characteristics of the KCNA1&#x2010;related phenotype.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="3" valign="top" colspan="1">EA1<xref rid="epi412934-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="epi412934-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="epi412934-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">E283K</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>ACZ (2)</p>
<p>CBZ (2)</p>
<p>LTG (3)</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Thr226Arg</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">PHT (2)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Epilepsy<xref rid="epi412934-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="epi412934-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" valign="top" colspan="1">EE<xref rid="epi412934-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="epi412934-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.888G&gt;T</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Leu296Phe</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">4&#x2010;AP (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.1102G&gt;C</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Val368Leu</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">OXC (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0001">
          <fn id="epi412934-note-0001">
            <p>Abbreviations: 4&#x2010;AP, 4&#x2010;aminopyridine; ACZ, acetazolamide; CBZ, carbamazepine; EA1, ictal ataxia type 1; EE, epileptic encephalopathy; GOF, gain of function; LOF, loss of function; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin sodium.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0002" content-type="TABLE">
        <label>TABLE 2</label>
        <caption>
          <p>Clinical characteristics of KCNA2&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/Treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="3" valign="top" colspan="1">EOEE<xref rid="epi412934-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="epi412934-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="epi412934-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.1214C&gt;T</p>
<p>c.788T&gt;C</p>
<p>c.1214C&gt;T</p>
<p>c.1214C&gt;T</p>
<p>c.894G&gt;T c.890G&gt;A</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Pro405Leu</p>
<p>p.Ile263Thr</p>
<p>p.Pro405Leu</p>
<p>p.Pro405Leu</p>
<p>p.Leu298Phe</p>
<p>p.Arg297Gln</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>GOF</p>
<p>GOF</p>
<p>GOF</p>
<p>GOF</p>
<p>LOF</p>
<p>LOF</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.706G&gt;A</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.E236K</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF and LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Truncated variant 1 case, 9 cases of missense variation</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.637C&gt;T</p>
<p>c.1192G&gt;T</p>
<p>c.1214C&gt;T</p>
<p>c.469G&gt;A</p>
<p>c.469G&gt;A</p>
<p>c.469G&gt;A</p>
<p>c.890G&gt;A</p>
<p>c.878T&gt;A c.982T&gt;G c.1120A&gt;G</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Gln213*</p>
<p>p.Gly398Cys</p>
<p>p.Pro405Leu</p>
<p>p.Glu157Lys</p>
<p>p.Glu157Lys</p>
<p>p.Glu157Lys</p>
<p>p.Arg297Gln</p>
<p>p.Leu293His</p>
<p>p.Leu328Val</p>
<p>p.Thr374Ala</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>3 cases of LOF</p>
<p>4 cases of GOF</p>
<p>3 cases of GOF and LOF</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">10</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">10</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Epilepsy phenotype (mild phenotype)<xref rid="epi412934-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.890G&gt;A</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Arg297Gln</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF&#x548C;LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">VPA&#x2009;+&#x2009;ESM (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" valign="top" colspan="1">PME<xref rid="epi412934-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.890G&gt;A</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Arg297Gln</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.890C&gt;A</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Arg297Gln</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">ACZ (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0002">
          <fn id="epi412934-note-0002">
            <p>Abbreviations: ACZ, acetazolamide; EOEE, early onset epileptic encephalopathy; ESM, ethosuximide; GOF, gain of function; LOF, loss of function; PME, progressive myoclonus; VPA, sodium valproate.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0003" content-type="TABLE">
        <label>TABLE 3</label>
        <caption>
          <p>Clinical characteristics of KCNB1&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/Treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.916C&gt;T</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.R306C</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GxTx (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Mild phenotype (autism, epilepsy, mental retardation)<xref rid="epi412934-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.595A&gt;T</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Ile199Phe</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Partial LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Sulthiame (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Epilepsy (mild phenotype)<xref rid="epi412934-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">No Sense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.1108G&gt;A</p>
<p>c.1747C&gt;T</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Trp370*</p>
<p>p.Arg583*</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">ACTH (2)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">EOEE<xref rid="epi412934-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Code shift</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p. Arg583*</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Full LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" rowspan="3" valign="top" colspan="1">Epilepsy (severe phenotype)<xref rid="epi412934-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="epi412934-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="epi412934-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">17 missense variants, 1 truncation variant</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.128A&gt;G</p>
<p>c.629C&gt;G</p>
<p>c.934C&gt;T</p>
<p>c.968C&gt;T</p>
<p>c.984C&gt;G</p>
<p>c.1001T&gt;C</p>
<p>c.1045G&gt;T</p>
<p>c.1105T&gt;C</p>
<p>c.1115C&gt;T</p>
<p>c.1130C&gt;A</p>
<p>c.1132G&gt;T</p>
<p>c.1139A&gt;G</p>
<p>c.1144G&gt;A</p>
<p>c.1180G&gt;A</p>
<p>c.1183G&gt;A</p>
<p>c.1226T&gt;C</p>
<p>c.1489G&gt;T</p>
<p>c.857del</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;p.A192Pfs*<xref rid="epi412934-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">18</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.586A&gt;T</p>
<p>c.829C&gt;T</p>
<p>c.1045G&gt;T</p>
<p>c.916C&gt;T</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Ile370Phe</p>
<p>p.Thr210Met</p>
<p>p.Val349Phe</p>
<p>p.Arg306Cys</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>VPA, ESM, CLN (1)</p>
<p>LTG (1)</p>
<p>VPA&#x3001;RFN (1)</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">4</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.990G&gt;C</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Glu330Asp</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LEV, VPA, OXC, PHB, ketogenic diet (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0003">
          <fn id="epi412934-note-0003">
            <p>Abbreviations: ACTH, adrenocorticotropic hormone; CLN (Clonazepam), clonazepam; EE, epileptic encephalopathy; ESM, ethosuximide; GOF, gain of function; GxTx, sodium channel blocker peptide guangxitoxin&#x2010;1; LEV, levetiracetam; LOF, loss of function; LTG, lamotrigine; EOEE, early onset epileptic encephalopathy; OXC, oxcarbazepine; PHB, phenobarbital; RFN (Rufinamid), lufenamide; VPA, valproate sodium.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0004" content-type="TABLE">
        <label>TABLE 4</label>
        <caption>
          <p>Clinical characteristics of KCNC1&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/Treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">PME<xref rid="epi412934-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.1262C&gt;T</p>
<p>c.1262C&gt;T</p>
<p>c.623G&gt;A</p>
<p>c.1196C&gt;T c.1262C&gt;T</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Ala421Val</p>
<p>p.Ala421Val</p>
<p>p.Cys208Tyr</p>
<p>p.Thr399Met</p>
<p>p.Ala421Val</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>Chlorpazan, TPM (1)</p>
<p>VPA, CLN (1)</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3</td>
              <td align="left" valign="top" rowspan="1" colspan="1">5</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">DEE<xref rid="epi412934-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.1262C&gt;T</p>
<p>c.1538C&gt;T</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Ala421Val</p>
<p>p.Ala513Val</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">VPA, VNS (2)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Mental retardation, malformations, no epilepsy<xref rid="epi412934-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">No Sense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.1015C&gt;T</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.R339*</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0004">
          <fn id="epi412934-note-0004">
            <p>Abbreviations: CLN, clonazepam; DEE, developmental epileptic encephalopathy; GOF, gain of function; LOF, loss of function; PME, progressive myoclonus; TPM (Topiramate), topiramate; VNS, vagus nerve stimulation; VPA, sodium valproate.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0005" content-type="TABLE">
        <label>TABLE 5</label>
        <caption>
          <p>Clinical characteristics of KCNQ2&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/Treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">BFNE<xref rid="epi412934-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">CBZ, LTG, OXC (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" rowspan="4" valign="top" colspan="1">eoee<xref rid="epi412934-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="epi412934-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>, <xref rid="epi412934-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="epi412934-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.638G&gt;A</p>
<p>c.821C&gt;T c.613A&gt;G</p>
<p>c.1678C&gt;T c.793G&gt;C c.1636A&gt;G c.869G&gt;A</p>
<p>c.869G&gt;A</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Arg213Gln</p>
<p>p.Thr274Met</p>
<p>p.Ile205Val</p>
<p>p.Arg560Trp</p>
<p>p.Ala265Pro</p>
<p>p.Met546Val</p>
<p>p.Gly290Asp</p>
<p>p.Gly290Asp</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Retigabine (1) LTG, TPM, ZNS (3)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">4</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.V175L</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>Y237C</p>
<p>I238V</p>
<p>F304S</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">EE<xref rid="epi412934-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0005">
          <fn id="epi412934-note-0005">
            <p>Abbreviations: BFNE, benign familial neonatal epilepsy; CBZ, carbamazepine; EE, epileptic encephalopathy; EOEE, early onset epileptic encephalopathy; GOF, gain of function; LOF, loss of function; LTG, lamotrigine; OXC, oxcarbazepine; TPM, topiramate; ZNS, zonisamide.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0006" content-type="TABLE">
        <label>TABLE 6</label>
        <caption>
          <p>Clinical characteristics of KCNQ3&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="2" valign="top" colspan="1">BFNE<xref rid="epi412934-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="epi412934-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2010;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">PHT (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">CBZ, OXC (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">BFIE<xref rid="epi412934-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">7 cases of missense variants, 3 cases of deletion variants</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.333_334delGT</p>
<p>c.1888delG</p>
<p>c.333_334delGT</p>
<p>c.619 C&gt;T</p>
<p>c.1057C&gt;G</p>
<p>c.1057 C&gt;G</p>
<p>c.587 A&gt;T</p>
<p>c.587 A&gt;T</p>
<p>c.1700T&gt;A</p>
<p>c.807G&gt;A</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Ser113HisfsX6</p>
<p>p.Val630SerfsX12</p>
<p>p.Ser113HisfsX6</p>
<p>p.Arg207Trp</p>
<p>p.Arg353Gly</p>
<p>p.Arg353Gly</p>
<p>p.Ala196Va</p>
<p>p.Ala196Val</p>
<p>p.Val567Asp</p>
<p>p.Trp269Ter</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">PHB, CBZ, VPA (10)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">10</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Mental retardation<xref rid="epi412934-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.689G&gt;A</p>
<p>c.688C&gt;A</p>
<p>c.689G&gt;A</p>
<p>c.688C&gt;T</p>
<p>c.688C&gt;T</p>
<p>c.688C&gt;T</p>
<p>c.689G&gt;A</p>
<p>c.688C&gt;T</p>
<p>c.688C&gt;T</p>
<p>c.680G&gt;A</p>
<p>c.680G&gt;A</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.R230H</p>
<p>p.R230S</p>
<p>p.R230H*</p>
<p>p.R230C</p>
<p>p.R230C</p>
<p>p.R230C</p>
<p>p.R230H</p>
<p>p.R230C</p>
<p>p.R230C</p>
<p>p.R227Q</p>
<p>p.R227Q</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">11</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0006">
          <fn id="epi412934-note-0006">
            <p>Abbreviations: BFIE, benign familial infantile epilepsy; BFNE, benign familial neonatal epilepsy; CBZ, carbamazepine; CBZ, carbamazepine; GOF, gain of function; LOF, loss of function; OXC, oxcarbazepine; PHB, phenobarbital; PHT, phenytoin sodium; VPA, valproate sodium.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0007" content-type="TABLE">
        <label>TABLE 7</label>
        <caption>
          <p>Clinical characteristics of KCNT1&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/Treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="4" valign="top" colspan="1">EIMFS<xref rid="epi412934-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>, <xref rid="epi412934-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>, <xref rid="epi412934-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref>, <xref rid="epi412934-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Phe932Ile</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.2800G&gt;A</td>
              <td align="left" valign="top" rowspan="1" colspan="1">A934T</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Quinidine (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Truncation</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">W476R A259D Q550del</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Cannabidiol (3)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.1283G&gt;A</p>
<p>c.1420C&gt;G</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Arg428Gln</p>
<p>p.Arg474Gly</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">PHB&#x3001;KBr (2)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" rowspan="3" valign="top" colspan="1">ANDFLE<xref rid="epi412934-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>, <xref rid="epi412934-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>, <xref rid="epi412934-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">STP, BZDs, LEV, ketogenic diet</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Quinidine (6)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.2800G&gt;A</p>
<p>c.862G&gt;A</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>A934T</p>
<p>G288S</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Quinidine (2)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0007">
          <fn id="epi412934-note-0007">
            <p>Abbreviations: ANDFLE, autosomal dominant nocturnal frontal lobe epilepsy; BZDs, benzodiazepines; EIMFS, infantile epilepsy with wandering focal seizures; GOF, gain of function; KBr, potassium bromide; LEV, levetiracetam; LOF, loss of function; PHB, phenobarbital; STP, stavudine.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0008" content-type="TABLE">
        <label>TABLE 8</label>
        <caption>
          <p>Clinical characteristics of KCNT2&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/Treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="3" valign="top" colspan="1">EIMFS<xref rid="epi412934-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>, <xref rid="epi412934-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>, <xref rid="epi412934-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1 case of code&#x2010;shift variant, 1 case of nonsense variant</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.L48Qfs43</p>
<p>p.K564*</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">LOF (2)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.991T&gt;A</p>
<p>c.592C&gt;G</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>p.Tyr331Asn</p>
<p>p.Gln198Glu</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">PHB (2)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.720T&gt;A</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Phe240Leu</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">PHB (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">DEE<xref rid="epi412934-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">c.569G&gt;C</td>
              <td align="left" valign="top" rowspan="1" colspan="1">p.Arg190Pro</td>
              <td align="left" valign="top" rowspan="1" colspan="1">GOF</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Quinidine (1)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0008">
          <fn id="epi412934-note-0008">
            <p>Abbreviations: EIMFS, infantile epilepsy with wandering focal seizures; GOF, gain of function; LOF, loss of function; PHB, phenobarbital.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="epi412934-tbl-0009" content-type="TABLE">
        <label>TABLE 9</label>
        <caption>
          <p>Clinical characteristics of KCNMA1&#x2010;related phenotypes.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Type of variant</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Mutant site</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Amino acid changes</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Functional effect</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs/Treatment effective (number of persons)</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Invalid/Number of persons</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Total cases</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">PNKD<xref rid="epi412934-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>c.2984 A&gt;G</p>
<p>c.2984 A&gt;G</p>
<p>c.2984 A&gt;G</p>
<p>&#x2013;</p>
<p>&#x2013;</p>
<p>c.2984 A&gt;G</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>N999S</p>
<p>N999S</p>
<p>N999S</p>
<p>N999S/R1128W</p>
<p>N999S/R1128W</p>
<p>N999S</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Amphetamine (6)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">0</td>
              <td align="left" valign="top" rowspan="1" colspan="1">6</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Epilepsy combined with movement disorders<xref rid="epi412934-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Missense</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>N999S</p>
<p>D434G</p>
<p>N999S/R1128W</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Paroxetine (3)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">ACZ (3)</td>
              <td align="left" valign="top" rowspan="1" colspan="1">3</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="epi412934-ntgp-0009">
          <fn id="epi412934-note-0009">
            <p>Abbreviations: ACZ, acetazolamide; GOF, gain of function; LOF, loss of function; PNKD, episodic nonkinesis&#x2010;induced movement disorder.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Therapeutically, KCNA1 gene variant&#x2010;associated epilepsy is phenotypically mild and can be self&#x2010;resolving in most individuals, and can be effectively controlled in severe individuals by administration of 4&#x2010;AP and OXC medications; the administration of 4&#x2010;AP, VPA, and ACZ was found to be effective in controlling epilepsy in KCNA2 gene variant&#x2010;associated epilepsy; and KCNB1 gene variant&#x2010;associated epilepsy exhibits a majority of resistance to medications, and it is recommended that the use of sultiame, a ketogenic dietary approaches to reduce the number of seizures; KCNC1 gene variant&#x2010;associated epilepsy is effectively treated with clobazam, clonazepam, TPM, and VPA; KCNH1&#x2010;associated epilepsy has a high degree of individual variability in the treatment of epilepsy, with some epilepsy being completely controlled, and some epilepsy being ineffectively treated with multidrug combinations; and for the treatment of epilepsy associated with the KCNQ2 and KCNQ3 gene variations, drugs such as CBZ, LTG, and OXC have shown to be effective in the treatment of the epilepsies. In addition, BZDs and quinidine can be used for KCNT1 and KCNT2 gene variant&#x2010;associated epilepsy; KBr, STP and LEV can be given for KCNT1 gene variant&#x2010;associated epilepsy; amphetamine and paroxetine are recommended for KCNMA1 gene variant&#x2010;associated seizures. However, it still needs to be pointed out that the association between gene phenotype and drug specificity is still greatly affected by individual variability.</p>
      <p>By summarizing the various potassium channel&#x2010;related gene phenotypes, functional studies, and therapeutic regimens and searching out the associations, we hope to provide some theoretical help for the precise and individualized treatment of epilepsy caused by potassium channel&#x2010;related gene mutations.</p>
    </sec>
    <sec id="epi412934-sec-0020">
      <title>AUTHOR CONTRIBUTIONS</title>
      <p>Zhao Tong was responsible for reviewing relevant literature, organizing the content of the literature and writing the paper; Wang Le was responsible for reading relevant literature and writing and revising the paper; Chen Fang was responsible for revising the paper, quality control and reviewing the manuscript, as well as overall supervision and management of the article.</p>
    </sec>
    <sec sec-type="COI-statement" id="epi412934-sec-0022">
      <title>CONFLICT OF INTEREST STATEMENT</title>
      <p>We declare no competing interests. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.</p>
    </sec>
  </body>
  <back>
    <ack id="epi412934-sec-0021">
      <title>ACKNOWLEDGMENTS</title>
      <p>We would like to thank the Hebei Provincial Children's Hospital and all the teachers who gave guidance for their help.</p>
    </ack>
    <ref-list content-type="cited-references" id="epi412934-bibl-0001">
      <title>REFERENCES</title>
      <ref id="epi412934-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0001">
<string-name>
<surname>Minglei</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Jinsheng</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Synaptophysin and epilepsy</article-title>. <source>Chin J Pract Neurol Dis</source>. <year>2010</year>;<volume>13</volume>(<issue>2</issue>):<fpage>75</fpage>&#x2013;<lpage>77</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0002">
<string-name>
<surname>Thijs</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Surges</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Sander</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Epilepsy in adults</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>393</volume>(<issue>10172</issue>):<fpage>689</fpage>&#x2013;<lpage>701</lpage>.<pub-id pub-id-type="pmid">30686584</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0003">
<string-name>
<surname>Xu</surname>
<given-names>X&#x2010;X</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>J&#x2010;H</given-names>
</string-name>. <article-title>Mutations of N&#x2010;methyl&#x2010;D&#x2010;aspartate receptor subunits in epilepsy</article-title>. <source>Neurosci Bull</source>. <year>2018</year>;<volume>34</volume>:<fpage>549</fpage>&#x2013;<lpage>565</lpage>.<pub-id pub-id-type="pmid">29124671</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0004">
<string-name>
<surname>Ademuwagun</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Rotimi</surname>
<given-names>SO</given-names>
</string-name>, <string-name>
<surname>Syrbe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ajamma</surname>
<given-names>YU</given-names>
</string-name>, <string-name>
<surname>Adebiyi</surname>
<given-names>E</given-names>
</string-name>. <article-title>Voltage gated sodium channel genes in epilepsy: mutations, functional studies, and treatment dimensions</article-title>. <source>Front Neurol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>600050</elocation-id>.<pub-id pub-id-type="pmid">33841294</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0005">
<string-name>
<surname>Oyrer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Maljevic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</string-name>, <string-name>
<surname>Berkovic</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Petrou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reid</surname>
<given-names>CA</given-names>
</string-name>. <article-title>Ion channels in genetic epilepsy: from genes and mechanisms to disease&#x2010;targeted therapies</article-title>. <source>Pharmacol Rev</source>. <year>2018</year>;<volume>70</volume>(<issue>1</issue>):<fpage>142</fpage>&#x2013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">29263209</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0006">
<string-name>
<surname>Nikitin</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Vinogradova</surname>
<given-names>LV</given-names>
</string-name>. <article-title>Potassium channels as prominent targets and tools for the treatment of epilepsy</article-title>. <source>Expert Opin Ther Targets</source>. <year>2021</year>;<volume>25</volume>(<issue>3</issue>):<fpage>223</fpage>&#x2013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">33754930</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0007">
<string-name>
<surname>Wickenden</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Potassium channels as anti&#x2010;epileptic drug targets</article-title>. <source>Neuropharmacology</source>. <year>2002</year>;<volume>43</volume>(<issue>7</issue>):<fpage>1055</fpage>&#x2013;<lpage>1060</lpage>.<pub-id pub-id-type="pmid">12504910</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0008">
<string-name>
<surname>Isomoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kurachi</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Inwardly rectifying potassium channels: their molecular heterogeneity and function</article-title>. <source>Jpn J Physiol</source>. <year>1997</year>;<volume>47</volume>(<issue>1</issue>):<fpage>11</fpage>&#x2013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">9159640</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0009">
<string-name>
<surname>Curran</surname>
<given-names>ME</given-names>
</string-name>. <article-title>Potassium ion channels and human disease: phenotypes to drug targets?</article-title>
<source>Curr Opin Biotechnol</source>. <year>1998</year>;<volume>9</volume>(<issue>6</issue>):<fpage>565</fpage>&#x2013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">9889143</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0010">
<string-name>
<surname>K&#xF6;hling</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wolfart</surname>
<given-names>J</given-names>
</string-name>. <article-title>Potassium channels in epilepsy</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2016</year>;<volume>6</volume>(<issue>5</issue>):<elocation-id>a022871</elocation-id>.<pub-id pub-id-type="pmid">27141079</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0011">
<string-name>
<surname>Pongs</surname>
<given-names>O</given-names>
</string-name>. <article-title>Voltage&#x2010;gated potassium channels: from hyperexcitability to excitement</article-title>. <source>FEBS Lett</source>. <year>1999</year>;<volume>452</volume>(<issue>1&#x2013;2</issue>):<fpage>31</fpage>&#x2013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">10376673</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0012">
<string-name>
<surname>Paulhus</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ammerman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Glasscock</surname>
<given-names>E</given-names>
</string-name>. <article-title>Clinical spectrum of KCNA1 mutations: new insights into episodic ataxia and epilepsy comorbidity[J]</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>8</issue>):<fpage>2802</fpage>.<pub-id pub-id-type="pmid">32316562</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0013">
<string-name>
<surname>Choi</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Episodic ataxias: clinical and genetic features</article-title>. <source>J Mov Disord</source>. <year>2016</year>;<volume>9</volume>(<issue>3</issue>):<fpage>129</fpage>.<pub-id pub-id-type="pmid">27667184</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0014">
<string-name>
<surname>Graves</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Cha</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Barohn</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Salajegheh</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Griggs</surname>
<given-names>RC</given-names>
</string-name>, et&#xA0;al. <article-title>Episodic ataxia type 1: clinical characterization, quality of life and genotype&#x2013;phenotype correlation</article-title>. <source>Brain</source>. <year>2014</year>;<volume>137</volume>(<issue>4</issue>):<fpage>1009</fpage>&#x2013;<lpage>1018</lpage>.<pub-id pub-id-type="pmid">24578548</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0015">
<string-name>
<surname>Escayg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>De Waard</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Bichet</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wolf</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mayer</surname>
<given-names>T</given-names>
</string-name>, et&#xA0;al. <article-title>Coding and noncoding variation of the human calcium&#x2010;channel &#x3B2;4&#x2010;subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia</article-title>. <source>Am J Human Genet</source>. <year>2000</year>;<volume>66</volume>(<issue>5</issue>):<fpage>1531</fpage>&#x2013;<lpage>1539</lpage>.<pub-id pub-id-type="pmid">10762541</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0016">
<string-name>
<surname>Imbrici</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Altamura</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gualandi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mangiatordi</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Neri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>de Maria</surname>
<given-names>G</given-names>
</string-name>, et&#xA0;al. <article-title>A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions</article-title>. <source>Mol Cell Neurosci</source>. <year>2017</year>;<volume>83</volume>:<fpage>6</fpage>&#x2013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">28666963</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0017">
<string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>von Hehn</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kaczmarek</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Ment</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Pober</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Hisama</surname>
<given-names>FM</given-names>
</string-name>. <article-title>Functional analysis of a novel potassium channel (KCNA1) mutation in hereditary myokymia</article-title>. <source>Neurogenetics</source>. <year>2007</year>;<volume>8</volume>:<fpage>131</fpage>&#x2013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">17136396</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0018">
<string-name>
<surname>Karalok</surname>
<given-names>ZS</given-names>
</string-name>, <string-name>
<surname>Megaro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cenciarini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Guven</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hasan</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Taskin</surname>
<given-names>BD</given-names>
</string-name>, et&#xA0;al. <article-title>Identification of a new de novo mutation underlying regressive episodic ataxia type I</article-title>. <source>Front Neurol</source>. <year>2018</year>;<volume>9</volume>:<elocation-id>587</elocation-id>.<pub-id pub-id-type="pmid">30140249</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0019">
<string-name>
<surname>Kinali</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jungbluth</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Eunson</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Sewry</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Manzur</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Mercuri</surname>
<given-names>E</given-names>
</string-name>, et&#xA0;al. <article-title>Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent episodic ataxia</article-title>. <source>Neuromuscul Disord</source>. <year>2004</year>;<volume>14</volume>(<issue>10</issue>):<fpage>689</fpage>&#x2013;<lpage>693</lpage>.<pub-id pub-id-type="pmid">15351427</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0020">
<string-name>
<surname>Eunson</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Rea</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zuberi</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Youroukos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Panayiotopoulos</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Liguori</surname>
<given-names>R</given-names>
</string-name>, et&#xA0;al. <article-title>Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability</article-title>. <source>Ann Neurol</source>. <year>2000</year>;<volume>48</volume>(<issue>4</issue>):<fpage>647</fpage>&#x2013;<lpage>656</lpage>.<pub-id pub-id-type="pmid">11026449</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0021">
<string-name>
<surname>Imbrici</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Grottesi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>D'Adamo</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Mannucci</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tucker</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Pessia</surname>
<given-names>M</given-names>
</string-name>. <article-title>Contribution of the central hydrophobic residue in the PXP motif of voltage&#x2010;dependent K+ channels to S6 flexibility and gating properties</article-title>. <source>Channels</source>. <year>2009</year>;<volume>3</volume>(<issue>1</issue>):<fpage>39</fpage>&#x2013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">19202350</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0022">
<string-name>
<surname>Harkin</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Iona</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Dibbens</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pelekanos</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Zuberi</surname>
<given-names>SM</given-names>
</string-name>, et&#xA0;al. <article-title>The spectrum of SCN1A&#x2010;related infantile epileptic encephalopathies</article-title>. <source>Brain</source>. <year>2007</year>;<volume>130</volume>(<issue>3</issue>):<fpage>843</fpage>&#x2013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">17347258</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0023">
<string-name>
<surname>M&#xFC;ller</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Takacs</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Hedrich</surname>
<given-names>UBS</given-names>
</string-name>, <string-name>
<surname>Coorg</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Masters</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Glinton</surname>
<given-names>KE</given-names>
</string-name>, et&#xA0;al. <article-title>KCNA1 gain&#x2010;of&#x2010;function epileptic encephalopathy treated with 4&#x2010;aminopyridine</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2023</year>;<volume>10</volume>(<issue>4</issue>):<fpage>656</fpage>&#x2013;<lpage>663</lpage>.<pub-id pub-id-type="pmid">36793218</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0024">
<string-name>
<surname>Verdura</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Fons</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schl&#xFC;ter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ruiz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fourcade</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Casasnovas</surname>
<given-names>C</given-names>
</string-name>, et&#xA0;al. <article-title>Complete loss of KCNA1 activity causes neonatal epileptic encephalopathy and dyskinesia</article-title>. <source>J Med Genet</source>. <year>2020</year>;<volume>57</volume>(<issue>2</issue>):<fpage>132</fpage>&#x2013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">31586945</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0025">
<string-name>
<surname>D&#xF6;ring</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Schr&#xF6;ter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>J&#xFC;ngling</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Biskup</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Klotz</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Bast</surname>
<given-names>T</given-names>
</string-name>, et&#xA0;al. <article-title>Refining genotypes and phenotypes in KCNA2&#x2010;related neurological disorders</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>6</issue>):<fpage>2824</fpage>.<pub-id pub-id-type="pmid">33802230</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0026">
<string-name>
<surname>Corbett</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Bellows</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Carroll</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Micallef</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Carvill</surname>
<given-names>GL</given-names>
</string-name>, et&#xA0;al. <article-title>Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy</article-title>. <source>Neurology</source>. <year>2016</year>;<volume>87</volume>(<issue>19</issue>):<fpage>1975</fpage>&#x2013;<lpage>1984</lpage>.<pub-id pub-id-type="pmid">27733563</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0027">
<string-name>
<surname>Masnada</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hedrich</surname>
<given-names>UBS</given-names>
</string-name>, <string-name>
<surname>Gardella</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Schubert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kaiwar</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Klee</surname>
<given-names>EW</given-names>
</string-name>, et&#xA0;al. <article-title>Clinical spectrum and genotype&#x2013;phenotype associations of KCNA2&#x2010;related encephalopathies</article-title>. <source>Brain</source>. <year>2017</year>;<volume>140</volume>(<issue>9</issue>):<fpage>2337</fpage>&#x2013;<lpage>2354</lpage>. Clinical spectrum.<pub-id pub-id-type="pmid">29050392</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0028">
<string-name>
<surname>Syrbe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hedrich</surname>
<given-names>UBS</given-names>
</string-name>, <string-name>
<surname>Riesch</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dj&#xE9;mi&#xE9;</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>M&#xFC;ller</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>M&#xF8;ller</surname>
<given-names>RS</given-names>
</string-name>, et&#xA0;al. <article-title>De novo loss&#x2010;or gain&#x2010;of&#x2010;function mutations in KCNA2 cause epileptic encephalopathy</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>(<issue>4</issue>):<fpage>393</fpage>&#x2013;<lpage>399</lpage>.<pub-id pub-id-type="pmid">25751627</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0029">
<string-name>
<surname>Imbrici</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Conte</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Blunck</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stregapede</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Liantonio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tosi</surname>
<given-names>M</given-names>
</string-name>, et&#xA0;al. <article-title>A novel KCNA2 mutation in a patient with non&#x2010;progressive congenital ataxia and epilepsy: functional characterization and sensitivity to 4&#x2010;aminopyridine</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>18</issue>):<fpage>9913</fpage>.<pub-id pub-id-type="pmid">34576077</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0030">
<string-name>
<surname>Hedrich</surname>
<given-names>UBS</given-names>
</string-name>, <string-name>
<surname>Lauxmann</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wolff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Synofzik</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bast</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Binelli</surname>
<given-names>A</given-names>
</string-name>, et&#xA0;al. <article-title>4&#x2010;Aminopyridine is a promising treatment option for patients with gain&#x2010;of&#x2010;function KCNA2&#x2010;encephalopathy</article-title>. <source>Sci Transl Med</source>. <year>2021</year>;<volume>13</volume>(<issue>609</issue>):<elocation-id>eaaz4957</elocation-id>.<pub-id pub-id-type="pmid">34516822</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0031">
<string-name>
<surname>Pena</surname>
<given-names>SDJ</given-names>
</string-name>, <string-name>
<surname>Coimbra</surname>
<given-names>RLM</given-names>
</string-name>. <article-title>Ataxia and myoclonic epilepsy due to a heterozygous new mutation in KCNA2: proposal for a new channelopathy</article-title>. <source>Clin Genet</source>. <year>2015</year>;<volume>87</volume>(<issue>2</issue>):<fpage>e1</fpage>&#x2013;<lpage>e3</lpage>.<pub-id pub-id-type="pmid">25477152</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0032">
<string-name>
<surname>Perilli</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Mastromoro</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Murciano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Amedeo</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Avenoso</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Pizzuti</surname>
<given-names>A</given-names>
</string-name>, et&#xA0;al. <article-title>Myoclonic epilepsy: case report of a mild phenotype in a pediatric patient expanding clinical Spectrum of KCNA2 pathogenic mutations</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>12</volume>:<fpage>2670</fpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0033">
<string-name>
<surname>Canafoglia</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Castellotti</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ragona</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Freri</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Granata</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chiapparini</surname>
<given-names>L</given-names>
</string-name>, et&#xA0;al. <article-title>Progressive myoclonus epilepsy caused by a gain&#x2010;of&#x2010;function KCNA2 mutation</article-title>. <source>Seizure</source>. <year>2019</year>;<volume>65</volume>:<fpage>106</fpage>&#x2013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">30660924</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0034">
<string-name>
<surname>Manole</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>M&#xE4;nnikk&#xF6;</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hanna</surname>
<given-names>MG</given-names>
</string-name>, <collab collab-type="authors">SYNAPS study group</collab>
, <string-name>
<surname>Kullmann</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Houlden</surname>
<given-names>H</given-names>
</string-name>, et&#xA0;al. <article-title>De novo KCNA2 mutations cause hereditary spastic paraplegia</article-title>. <source>Ann Neurol</source>. <year>2017</year>;<volume>81</volume>(<issue>2</issue>):<fpage>326</fpage>&#x2013;<lpage>328</lpage>.<pub-id pub-id-type="pmid">28032718</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0035">
<string-name>
<surname>Yu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Parakramaweera</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gowda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sharad</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Thakker&#x2010;Varia</surname>
<given-names>S</given-names>
</string-name>, et&#xA0;al. <article-title>Oxidation of KCNB1 potassium channels causes neurotoxicity and cognitive impairment in a mouse model of traumatic brain injury</article-title>. <source>J Neurosci</source>. <year>2016</year>;<volume>36</volume>(<issue>43</issue>):<fpage>11084</fpage>&#x2013;<lpage>11096</lpage>.<pub-id pub-id-type="pmid">27798188</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0036">
<string-name>
<surname>Torkamani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bersell</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jorge</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Bjork</surname>
<given-names>RL</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Friedman</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Bloss</surname>
<given-names>CS</given-names>
</string-name>, et&#xA0;al. <article-title>De novo KCNB1 mutations in epileptic encephalopathy</article-title>. <source>Ann Neurol</source>. <year>2014</year>;<volume>76</volume>(<issue>4</issue>):<fpage>529</fpage>&#x2013;<lpage>540</lpage>.<pub-id pub-id-type="pmid">25164438</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0037">
<string-name>
<surname>Saitsu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Akita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tohyama</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Goldberg&#x2010;Stern</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>R</given-names>
</string-name>, et&#xA0;al. <article-title>De novo KCNB1 mutations in infantile epilepsy inhibit repetitive neuronal firing</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>(<issue>1</issue>):<fpage>15199</fpage>.<pub-id pub-id-type="pmid">26477325</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0038">
<string-name>
<surname>Liu</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Bean</surname>
<given-names>BP</given-names>
</string-name>. <article-title>Kv2 channel regulation of action potential repolarization and firing patterns in superior cervical ganglion neurons and hippocampal CA1 pyramidal neurons</article-title>. <source>J Neurosci</source>. <year>2014</year>;<volume>34</volume>(<issue>14</issue>):<fpage>4991</fpage>&#x2013;<lpage>5002</lpage>.<pub-id pub-id-type="pmid">24695716</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0039">
<string-name>
<surname>Lu</surname>
<given-names>J&#x2010;M</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>J&#x2010;F</given-names>
</string-name>, <string-name>
<surname>Ji</surname>
<given-names>C&#x2010;H</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>K</given-names>
</string-name>. <article-title>Mild phenotype in a patient with developmental and epileptic encephalopathy carrying a novel de novo KCNB1 mutation</article-title>. <source>Neurol Sci</source>. <year>2021</year>;<volume>42</volume>(<issue>10</issue>):<fpage>4325</fpage>&#x2013;<lpage>4327</lpage>.<pub-id pub-id-type="pmid">34176003</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0040">
<string-name>
<surname>Calhoun</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Vanoye</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Kok</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>AL</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Kearney</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Characterization of a KCNB1 mutation associated with autism, intellectual disability, and epilepsy</article-title>. <source>Neurol Genet</source>. <year>2017</year>;<volume>3</volume>(<issue>6</issue>):<elocation-id>e198</elocation-id>.<pub-id pub-id-type="pmid">29264390</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0041">
<string-name>
<surname>Bar</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Barcia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jennesson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>le Guyader</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mignot</surname>
<given-names>C</given-names>
</string-name>, et&#xA0;al. <article-title>Expanding the genetic and phenotypic relevance of KCNB1 mutations in developmental and epileptic encephalopathies: 27 new patients and overview of the literature</article-title>. <source>Hum Mutat</source>. <year>2020</year>;<volume>41</volume>(<issue>1</issue>):<fpage>69</fpage>&#x2013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">31513310</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0042">
<string-name>
<surname>Xiong</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kessi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Duan</surname>
<given-names>H</given-names>
</string-name>, et&#xA0;al. <article-title>Correlation analyses of clinical manifestations and mutation effects in KCNB1&#x2010;related neurodevelopmental disorder</article-title>. <source>Front Pediat</source>. <year>2022</year>;<volume>9</volume>:<elocation-id>755344</elocation-id>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0043">
<string-name>
<surname>Kovel</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Carolien</surname>
<given-names>GF</given-names>
</string-name>, et&#xA0;al. <article-title>Neurodevelopmental disorders caused by de novo mutations in KCNB1 genotypes and phenotypes</article-title>. <source>JAMA Neurol</source>. <year>2017</year>;<volume>74</volume>(<issue>10</issue>):<fpage>1228</fpage>&#x2013;<lpage>1236</lpage>.<pub-id pub-id-type="pmid">28806457</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0044">
<string-name>
<surname>Marini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Romoli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Parrini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mei</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mari</surname>
<given-names>F</given-names>
</string-name>, et&#xA0;al. <article-title>"clinical features and outcome of 6 new patients carrying de novo KCNB1 gene mutations." neurology</article-title>. <source>Genetics</source>. <year>2017</year>;<volume>3</volume>:<fpage>6</fpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0045">
<string-name>
<surname>Miao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, et&#xA0;al. <article-title>Genotype and phenotype analysis using an epilepsy&#x2010;associated gene panel in Chinese pediatric epilepsy patients</article-title>. <source>Clin Genet</source>. <year>2018</year>;<volume>94</volume>(<issue>6</issue>):<fpage>512</fpage>&#x2013;<lpage>520</lpage>.<pub-id pub-id-type="pmid">30182498</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0046">
<string-name>
<surname>Oliver</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Franceschetti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Milligan</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Muona</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mandelstam</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Canafoglia</surname>
<given-names>L</given-names>
</string-name>, et&#xA0;al. <article-title>Myoclonus epilepsy and ataxia due to KCNC 1 mutation: analysis of 20 cases and K+ channel properties</article-title>. <source>Ann Neurol</source>. <year>2017</year>;<volume>81</volume>(<issue>5</issue>):<fpage>677</fpage>&#x2013;<lpage>689</lpage>.<pub-id pub-id-type="pmid">28380698</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0047">
<string-name>
<surname>Nascimento</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations</article-title>. <source>Epileptic Disord</source>. <year>2016</year>;<volume>18</volume>(<issue>s2</issue>):<fpage>S135</fpage>&#x2013;<lpage>S138</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0048">
<string-name>
<surname>Park</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Koko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hedrich</surname>
<given-names>UBS</given-names>
</string-name>, <string-name>
<surname>Hermann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cremer</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Haberlandt</surname>
<given-names>E</given-names>
</string-name>, et&#xA0;al. <article-title>KCNC1&#x2010;related disorders: new de novo mutations expand the phenotypic spectrum</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2019</year>;<volume>6</volume>(<issue>7</issue>):<fpage>1319</fpage>&#x2013;<lpage>1326</lpage>.<pub-id pub-id-type="pmid">31353862</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0049">
<string-name>
<surname>Cameron</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Maljevic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nair</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Aung</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Cogn&#xE9;</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>B&#xE9;zieau</surname>
<given-names>S</given-names>
</string-name>, et&#xA0;al. <article-title>Encephalopathies with KCNC1 mutations: genotype&#x2010;phenotype&#x2010;functional correlations</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2019</year>;<volume>6</volume>(<issue>7</issue>):<fpage>1263</fpage>&#x2013;<lpage>1272</lpage>.<pub-id pub-id-type="pmid">31353855</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0050">
<string-name>
<surname>Poirier</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Viot</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lombardi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jauny</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Billuart</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bienvenu</surname>
<given-names>T</given-names>
</string-name>. <article-title>Loss of function of KCNC1 is associated with intellectual disability without seizures</article-title>. <source>Eur J Hum Genet</source>. <year>2017</year>;<volume>25</volume>(<issue>5</issue>):<fpage>560</fpage>&#x2013;<lpage>564</lpage>.<pub-id pub-id-type="pmid">28145425</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0051">
<string-name>
<surname>Bramswig</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Ockeloen</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Czeschik</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>van Essen</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Pfundt</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Smeitink</surname>
<given-names>J</given-names>
</string-name>, et&#xA0;al. <article-title>&#x2018;Splitting versus lumping&#x2019;: Temple&#x2013;Baraitser and Zimmermann&#x2013;Laband syndromes</article-title>. <source>Hum Genet</source>. <year>2015</year>;<volume>134</volume>:<fpage>1089</fpage>&#x2013;<lpage>1097</lpage>.<pub-id pub-id-type="pmid">26264464</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0052">
<string-name>
<surname>Kort&#xFC;m</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Caputo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Stella</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ciolfi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alawi</surname>
<given-names>M</given-names>
</string-name>, et&#xA0;al. <article-title>Mutations in KCNH1 and ATP6V1B2 cause Zimmermann&#x2010;Laband syndrome</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>(<issue>6</issue>):<fpage>661</fpage>&#x2013;<lpage>667</lpage>.<pub-id pub-id-type="pmid">25915598</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0053">
        <label>53</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0053">
<string-name>
<surname>Simons</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rash</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cristofori&#x2010;Armstrong</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>D</given-names>
</string-name>, et&#xA0;al. <article-title>Mutations in the voltage&#x2010;gated potassium channel gene KCNH1 cause Temple&#x2010;Baraitser syndrome and epilepsy</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>(<issue>1</issue>):<fpage>73</fpage>&#x2013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">25420144</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0054">
        <label>54</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0054">
<string-name>
<surname>Mucca</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Patat</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Whalen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Arnaud</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Barcia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Buratti</surname>
<given-names>J</given-names>
</string-name>, et&#xA0;al. <article-title>Patients with KCNH1&#x2010;related intellectual disability without distinctive features of Zimmermann&#x2010;Laband/Temple&#x2010;Baraitser syndrome</article-title>. <source>J Med Genet</source>. <year>2022</year>;<volume>59</volume>(<issue>5</issue>):<fpage>505</fpage>&#x2013;<lpage>510</lpage>.<pub-id pub-id-type="pmid">33811134</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0055">
        <label>55</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0055">
<string-name>
<surname>von Wrede</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jeub</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ari&#xF6;z</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Elger</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>von Voss</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>H&#x2010;G</given-names>
</string-name>, et&#xA0;al. <article-title>Novel KCNH1 mutations associated with epilepsy: broadening the phenotypic spectrum of KCNH1&#x2010;associated diseases</article-title>. <source>Genes</source>. <year>2021</year>;<volume>12</volume>(<issue>2</issue>):<fpage>132</fpage>.<pub-id pub-id-type="pmid">33494179</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0056">
        <label>56</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0056">
<string-name>
<surname>Gao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Dai</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>Y&#x2010;Y</given-names>
</string-name>. <article-title>Genetic architecture and phenotypic landscape of deafness and onychodystrophy syndromes</article-title>. <source>Hum Genet</source>. <year>2022</year>;<volume>141</volume>(<issue>3&#x2013;4</issue>):<fpage>821</fpage>&#x2013;<lpage>838</lpage>.<pub-id pub-id-type="pmid">34232384</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0057">
        <label>57</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0057">
<string-name>
<surname>Tian</surname>
<given-names>M&#x2010;Q</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>R&#x2010;K</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Shu</surname>
<given-names>X&#x2010;M</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, et&#xA0;al. <article-title>Phenotypic expansion of KCNH1&#x2010;associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub&#x2010;regional locations</article-title>. <source>CNS Neurosci Ther</source>. <year>2023</year>;<volume>29</volume>(<issue>1</issue>):<fpage>270</fpage>&#x2013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">36285361</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0058">
        <label>58</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0058">
<string-name>
<surname>Mastrangelo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</string-name>, <string-name>
<surname>Bramswig</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Nair</surname>
<given-names>LDV</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Dentici</surname>
<given-names>ML</given-names>
</string-name>, et&#xA0;al. <article-title>Epilepsy in KCNH1&#x2010;related syndromes</article-title>. <source>Epileptic Disord</source>. <year>2016</year>;<volume>18</volume>(<issue>2</issue>):<fpage>123</fpage>&#x2013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">27267311</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0059">
        <label>59</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0059">
<string-name>
<surname>Weckhuysen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mandelstam</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Suls</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Audenaert</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Deconinck</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Claes</surname>
<given-names>LRF</given-names>
</string-name>, et&#xA0;al. <article-title>KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy</article-title>. <source>Ann Neurol</source>. <year>2012</year>;<volume>71</volume>(<issue>1</issue>):<fpage>15</fpage>&#x2013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">22275249</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0060">
        <label>60</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0060">
<string-name>
<surname>Rett</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Teubel</surname>
<given-names>R</given-names>
</string-name>. <article-title>Neonatal convulsions in a family with epilepsy</article-title>. <source>Wien Klin Wochenschr</source>. <year>1964</year>;<volume>76</volume>:<fpage>609</fpage>&#x2013;<lpage>613</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0061">
        <label>61</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0061">
<string-name>
<surname>Kuersten</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tacke</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gerstl</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hoelz</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>St&#xFC;lpnagel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Borggraefe</surname>
<given-names>I</given-names>
</string-name>. <article-title>Antiepileptic therapy approaches in KCNQ2 related epilepsy: a systematic review</article-title>. <source>Eur J Med Genet</source>. <year>2020</year>;<volume>63</volume>(<issue>1</issue>):<elocation-id>103628</elocation-id>.<pub-id pub-id-type="pmid">30771507</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0062">
        <label>62</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0062">
<string-name>
<surname>Miceli</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Soldovieri</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Ambrosino</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>De Maria</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Migliore</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Migliore</surname>
<given-names>R</given-names>
</string-name>, et&#xA0;al. <article-title>Early&#x2010;onset epileptic encephalopathy caused by gain&#x2010;of&#x2010;function mutations in the voltage sensor of Kv7. 2 and Kv7. 3 potassium channel subunits</article-title>. <source>J Neurosci</source>. <year>2015</year>;<volume>35</volume>(<issue>9</issue>):<fpage>3782</fpage>&#x2013;<lpage>3793</lpage>.<pub-id pub-id-type="pmid">25740509</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0063">
        <label>63</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0063">
<string-name>
<surname>Weckhuysen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ivanovic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Hendrickx</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>van Coster</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hjalgrim</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>M&#xF8;ller</surname>
<given-names>RS</given-names>
</string-name>, et&#xA0;al. <article-title>Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>81</volume>(<issue>19</issue>):<fpage>1697</fpage>&#x2013;<lpage>1703</lpage>.<pub-id pub-id-type="pmid">24107868</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0064">
        <label>64</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0064">
<string-name>
<surname>Yang</surname>
<given-names>N&#x2010;D</given-names>
</string-name>, <string-name>
<surname>Kanyo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Dou</surname>
<given-names>AK</given-names>
</string-name>, et&#xA0;al. <article-title>Electro&#x2010;mechanical coupling of KCNQ channels is a target of epilepsy&#x2010;associated mutations and retigabine</article-title>. <source>Sci Adv</source>. <year>2022</year>;<volume>8</volume>(<issue>29</issue>):<elocation-id>eabo3625</elocation-id>.<pub-id pub-id-type="pmid">35857840</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0065">
        <label>65</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0065">
<string-name>
<surname>Kalappa</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Soh</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Duignan</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Furuya</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tzingounis</surname>
<given-names>AV</given-names>
</string-name>, et&#xA0;al. <article-title>Potent KCNQ2/3&#x2010;specific channel activator suppresses in&#xA0;vivo epileptic activity and prevents the development of tinnitus</article-title>. <source>J Neurosci</source>. <year>2015</year>;<volume>35</volume>(<issue>23</issue>):<fpage>8829</fpage>&#x2013;<lpage>8842</lpage>.<pub-id pub-id-type="pmid">26063916</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0066">
        <label>66</label>
        <mixed-citation publication-type="book" id="epi412934-cit-0066">
<string-name>
<surname>Miceli</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Soldovieri</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Joshi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<given-names>Edward C.</given-names>
<surname>Cooper</surname>
</string-name>, <string-name>
<given-names>Maurizio</given-names>
<surname>Taglialatela</surname>
</string-name>
<source>KCNQ3&#x2010;related disorders</source>. <publisher-name>GeneReviews&#x5E90; &#x2010; NCBI Bookshelf[J]</publisher-name>. <publisher-loc>University of Washington Seattle</publisher-loc>. <year>2014</year> [Updated 2017 Sep 7].</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0067">
        <label>67</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0067">
<string-name>
<surname>Milh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lacoste</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cacciagli</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Abidi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sutera&#x2010;Sardo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tzelepis</surname>
<given-names>I</given-names>
</string-name>, et&#xA0;al. <article-title>Variable clinical expression in patients with mosaicism for KCNQ2 mutations</article-title>. <source>Am J Med Genet A</source>. <year>2015</year>;<volume>167</volume>(<issue>10</issue>):<fpage>2314</fpage>&#x2013;<lpage>2318</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0068">
        <label>68</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0068">
<string-name>
<surname>Miceli</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Striano</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Soldovieri</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Fontana</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nardello</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Robbiano</surname>
<given-names>A</given-names>
</string-name>, et&#xA0;al. <article-title>A novel KCNQ3 mutation in familial epilepsy with focal seizures and intellectual disability</article-title>. <source>Epilepsia</source>. <year>2015</year>;<volume>56</volume>(<issue>2</issue>):<fpage>e15</fpage>&#x2013;<lpage>e20</lpage>.<pub-id pub-id-type="pmid">25524373</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0069">
        <label>69</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0069">
<string-name>
<surname>Painter</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Pippenger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wasterlain</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Barmada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pitlick</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>G</given-names>
</string-name>, et&#xA0;al. <article-title>Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution</article-title>. <source>Neurology</source>. <year>1981</year>;<volume>31</volume>(<issue>9</issue>):<fpage>1107</fpage>.<pub-id pub-id-type="pmid">7196530</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0070">
        <label>70</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0070">
<string-name>
<surname>Tulloch</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Carr</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Ensom</surname>
<given-names>MH</given-names>
</string-name>. <article-title>A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures</article-title>. <source>J Pediatr Pharmacol Ther</source>. <year>2012</year>;<volume>17</volume>(<issue>1</issue>):<fpage>31</fpage>&#x2013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">23118657</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0071">
        <label>71</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0071">
<string-name>
<surname>Sands</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Balestri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bellini</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mulkey</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Danhaive</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Bakken</surname>
<given-names>EH</given-names>
</string-name>, et&#xA0;al. <article-title>Rapid and safe response to low&#x2010;dose carbamazepine in neonatal epilepsy</article-title>. <source>Epilepsia</source>. <year>2016</year>;<volume>57</volume>(<issue>12</issue>):<fpage>2019</fpage>&#x2013;<lpage>2030</lpage>.<pub-id pub-id-type="pmid">27888506</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0072">
        <label>72</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0072">
<article-title>De novo mutations in epileptic encephalopathies</article-title>. <source>Nature</source>. <year>2013</year>;<volume>501</volume>(<issue>7466</issue>):<fpage>217</fpage>&#x2013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">23934111</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0073">
        <label>73</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0073">
<article-title>Prevalence and architecture of de novo mutations in developmental disorders</article-title>. <source>Nature</source>. <year>2017</year>;<volume>542</volume>(<issue>7642</issue>):<fpage>433</fpage>&#x2013;<lpage>438</lpage>.<pub-id pub-id-type="pmid">28135719</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0074">
        <label>74</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0074">
<string-name>
<surname>Sands</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Miceli</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lesca</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Beck</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Sadleir</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Arrington</surname>
<given-names>DK</given-names>
</string-name>, et&#xA0;al. <article-title>Autism and developmental disability caused by KCNQ3 gain&#x2010;of&#x2010;function mutations</article-title>. <source>Ann Neurol</source>. <year>2019</year>;<volume>86</volume>(<issue>2</issue>):<fpage>181</fpage>&#x2013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">31177578</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0075">
        <label>75</label>
        <mixed-citation publication-type="book" id="epi412934-cit-0075">
<string-name>
<surname>Gertler</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bearden</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bhattacharjee</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Carvill</surname>
<given-names>G.</given-names>
</string-name>
<source>KCNT1&#x2010;related epilepsy</source>. <publisher-name>Book from University of Washington</publisher-name>, <publisher-loc>Seattle, Seattle (WA)</publisher-loc>, 1993. 21 Sep <year>2018</year>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0076">
        <label>76</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0076">
<string-name>
<surname>Evely</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Pryce</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Bhattacharjee</surname>
<given-names>A</given-names>
</string-name>. <article-title>The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss&#x2010;of&#x2010;function channel phenotype</article-title>. <source>Neuroscience</source>. <year>2017</year>;<volume>351</volume>:<fpage>65</fpage>&#x2013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">28366665</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0077">
        <label>77</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0077">
<string-name>
<surname>Cole</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Dejakaisaya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pilati</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fishwick</surname>
<given-names>CWG</given-names>
</string-name>, <string-name>
<surname>Muench</surname>
<given-names>SP</given-names>
</string-name>, et&#xA0;al. <article-title>Structure&#x2010;based identification and characterization of inhibitors of the epilepsy&#x2010;associated KNa1. 1 (KCNT1) potassium channel</article-title>. <source>IScience</source>. <year>2020</year>;<volume>23</volume>(<issue>5</issue>):<elocation-id>101100</elocation-id>.<pub-id pub-id-type="pmid">32408169</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0078">
        <label>78</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0078">
<string-name>
<surname>McTague</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nair</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Malhotra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Trump</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gazina</surname>
<given-names>EV</given-names>
</string-name>, et&#xA0;al. <article-title>Clinical and molecular characterization of KCNT1&#x2010;related severe early&#x2010;onset epilepsy</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>90</volume>(<issue>1</issue>):<fpage>e55</fpage>&#x2013;<lpage>e66</lpage>.<pub-id pub-id-type="pmid">29196579</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0079">
        <label>79</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0079">
<string-name>
<surname>Fitzgerald</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Fiannacca</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Gertler</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Gunning</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Syrbe</surname>
<given-names>S</given-names>
</string-name>, et&#xA0;al. <article-title>Treatment responsiveness in KCNT1&#x2010;related epilepsy</article-title>. <source>Neurotherapeutics</source>. <year>2019</year>;<volume>16</volume>:<fpage>848</fpage>&#x2013;<lpage>857</lpage>.<pub-id pub-id-type="pmid">31054119</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0080">
        <label>80</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0080">
<string-name>
<surname>Poisson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cilio</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: an open&#x2010;label, prospective, interventional study</article-title>. <source>Eur J Paediatr Neurol</source>. <year>2020</year>;<volume>25</volume>:<fpage>77</fpage>&#x2013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">31926846</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0081">
        <label>81</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0081">
<string-name>
<surname>Datta</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Michoulas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Guella</surname>
<given-names>I</given-names>
</string-name>, <collab collab-type="authors">EPGEN Study</collab>
, <string-name>
<surname>Demos</surname>
<given-names>M</given-names>
</string-name>. <article-title>Two patients with KCNT1&#x2010;related epilepsy responding to phenobarbital and potassium bromide</article-title>. <source>J Child Neurol</source>. <year>2019</year>;<volume>34</volume>(<issue>12</issue>):<fpage>728</fpage>&#x2013;<lpage>734</lpage>.<pub-id pub-id-type="pmid">31208268</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0082">
        <label>82</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0082">
<string-name>
<surname>Mullen</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Carney</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Roten</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ching</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lightfoot</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Churilov</surname>
<given-names>L</given-names>
</string-name>, et&#xA0;al. <article-title>Precision therapy for epilepsy due to KCNT1 mutations: a randomized trial of oral quinidine</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>90</volume>(<issue>1</issue>):<fpage>e67</fpage>&#x2013;<lpage>e72</lpage>.<pub-id pub-id-type="pmid">29196578</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0083">
        <label>83</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0083">
<string-name>
<surname>Hansen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Widman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hattingen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Elger</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Kunz</surname>
<given-names>WS</given-names>
</string-name>. <article-title>Mesial temporal lobe epilepsy associated with KCNT1 mutation</article-title>. <source>Seizure</source>. <year>2017</year>;<volume>45</volume>:<fpage>181</fpage>&#x2013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">28081520</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0084">
        <label>84</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0084">
<string-name>
<surname>Madaan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jauhari</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chakrabarty</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gulati</surname>
<given-names>S</given-names>
</string-name>. <article-title>A quinidine non responsive novel KCNT1 mutation in an Indian infant with epilepsy of infancy with migrating focal seizures</article-title>. <source>Brain Dev</source>. <year>2018</year>;<volume>40</volume>(<issue>3</issue>):<fpage>229</fpage>&#x2013;<lpage>232</lpage>.<pub-id pub-id-type="pmid">29037447</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0085">
        <label>85</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0085">
<string-name>
<surname>Gong</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jiao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Case report: causative De novo mutations of KCNT2 for developmental and epileptic encephalopathy</article-title>. <source>Front Genet</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>649556</elocation-id>.<pub-id pub-id-type="pmid">34276763</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0086">
        <label>86</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0086">
<string-name>
<surname>Mao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Bruneau</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Becq</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Xi</surname>
<given-names>H</given-names>
</string-name>, et&#xA0;al. <article-title>The epilepsy of infancy with migrating focal seizures: identification of de novo mutations of the KCNT2 gene that exert inhibitory effects on the corresponding heteromeric KNa1. 1/KNa1. 2 potassium channel</article-title>. <source>Front Cell Neurosci</source>. <year>2020</year>;<volume>14</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">32038177</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0087">
        <label>87</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0087">
<string-name>
<surname>Gururaj</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Sheehan</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Kandula</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Macintosh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ying</surname>
<given-names>K</given-names>
</string-name>, et&#xA0;al. <article-title>A de novo mutation in the sodium&#x2010;activated potassium channel KCNT2 alters ion selectivity and causes epileptic encephalopathy</article-title>. <source>Cell Rep</source>. <year>2017</year>;<volume>21</volume>(<issue>4</issue>):<fpage>926</fpage>&#x2013;<lpage>933</lpage>.<pub-id pub-id-type="pmid">29069600</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0088">
        <label>88</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0088">
<string-name>
<surname>Ambrosino</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Soldovieri</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Bast</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Turnpenny</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Uhrig</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Biskup</surname>
<given-names>S</given-names>
</string-name>, et&#xA0;al. <article-title>De novo gain&#x2010;of&#x2010;function mutations in KCNT2 as a novel cause of developmental and epileptic encephalopathy</article-title>. <source>Ann Neurol</source>. <year>2018</year>;<volume>83</volume>(<issue>6</issue>):<fpage>1198</fpage>&#x2013;<lpage>1204</lpage>.<pub-id pub-id-type="pmid">29740868</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0089">
        <label>89</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0089">
<string-name>
<surname>Inuzuka</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Macedo&#x2010;Souza</surname>
<given-names>LI</given-names>
</string-name>, <string-name>
<surname>Della&#x2010;Ripa</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Monteiro</surname>
<given-names>FP</given-names>
</string-name>, <string-name>
<surname>Ramos</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kitajima</surname>
<given-names>JP</given-names>
</string-name>, et&#xA0;al. <article-title>Additional observation of a de novo pathogenic mutation in KCNT2 leading to epileptic encephalopathy with clinical features of frontal lobe epilepsy</article-title>. <source>Brain Dev</source>. <year>2020</year>;<volume>42</volume>(<issue>9</issue>):<fpage>691</fpage>&#x2013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">32773162</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0090">
        <label>90</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0090">
<string-name>
<surname>Jackson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Banka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>H</given-names>
</string-name>, <collab collab-type="authors">Genomics England Research Consortium</collab>
, <string-name>
<surname>Robinson</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lovell</surname>
<given-names>S</given-names>
</string-name>, et&#xA0;al. <article-title>Recurrent KCNT2 missense mutations affecting p. Arg190 result in a recognizable phenotype</article-title>. <source>Am J Med Genet A</source>. <year>2021</year>;<volume>185</volume>(<issue>10</issue>):<fpage>3083</fpage>&#x2013;<lpage>3091</lpage>.<pub-id pub-id-type="pmid">34061450</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0091">
        <label>91</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0091">
<string-name>
<surname>Tian</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xiaojing</surname>
<given-names>LI</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hou</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>B</given-names>
</string-name>, et&#xA0;al. <article-title>Analysis of a family with inherited generalized epilepsy with febrile seizures plus caused by the KCNT2 mutation and literature review</article-title>. <source>Chin J Appl Clin Pediatr</source>. <year>2021</year>;<volume>36</volume>;<fpage>136</fpage>&#x2013;<lpage>139</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0092">
        <label>92</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0092">
<string-name>
<surname>Zang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>. <article-title>The large conductance calcium&#x2010;and voltage&#x2010;activated potassium channel (BK) and epilepsy</article-title>. <source>CNS Neurol Disord Drug Target</source>. <year>2018</year>;<volume>17</volume>;<fpage>248</fpage>&#x2013;<lpage>254</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0093">
        <label>93</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0093">
<string-name>
<surname>Lee</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>J</given-names>
</string-name>. <article-title>BK channel activation: structural and functional insights</article-title>. <source>Trends Neurosci</source>. <year>2010</year>;<volume>33</volume>(<issue>9</issue>):<fpage>415</fpage>&#x2013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">20663573</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0094">
        <label>94</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0094">
<string-name>
<surname>Sausbier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Arntz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Feil</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kamm</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Adelsberger</surname>
<given-names>H</given-names>
</string-name>, et&#xA0;al. <article-title>Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+&#x2212;activated K+ channel deficiency</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2004</year>;<volume>101</volume>:<fpage>9474</fpage>&#x2013;<lpage>9478</lpage>.<pub-id pub-id-type="pmid">15194823</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0095">
        <label>95</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0095">
<string-name>
<surname>Bailey</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Moldenhauer</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Keros</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Meredith</surname>
<given-names>AL</given-names>
</string-name>. <article-title>KCNMA1&#x2010;linked channelopathy</article-title>. <source>J General Physiol</source>. <year>2019</year>;<volume>151</volume>(<issue>10</issue>):<fpage>1173</fpage>&#x2013;<lpage>1189</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0096">
        <label>96</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0096">
<string-name>
<surname>Miller</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Moldenhauer</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Keros</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Meredith</surname>
<given-names>AL</given-names>
</string-name>. <article-title>An emerging spectrum of mutations and clinical features in KCNMA1&#x2010;linked channelopathy</article-title>. <source>Channels</source>. <year>2021</year>;<volume>15</volume>(<issue>1</issue>):<fpage>447</fpage>&#x2013;<lpage>464</lpage>.<pub-id pub-id-type="pmid">34224328</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0097">
        <label>97</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0097">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Bao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>X</given-names>
</string-name>. <article-title>KCNMA1 mutation in children with paroxysmal dyskinesia and epilepsy: case report and literature review</article-title>. <source>Transl Sci Rare Dis</source>. <year>2017</year>;<volume>2</volume>(<issue>3&#x2013;4</issue>):<fpage>165</fpage>&#x2013;<lpage>173</lpage>.</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0098">
        <label>98</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0098">
<string-name>
<surname>Moldenhauer</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Matychak</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Meredith</surname>
<given-names>AL</given-names>
</string-name>. <article-title>Comparative gain&#x2010;of&#x2010;function effects of the KCNMA1&#x2010;N999S mutation on human BK channel properties</article-title>. <source>J Neurophysiol</source>. <year>2020</year>;<volume>123</volume>(<issue>2</issue>):<fpage>560</fpage>&#x2013;<lpage>570</lpage>.<pub-id pub-id-type="pmid">31851553</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0099">
        <label>99</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0099">
<string-name>
<surname>Keros</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Heim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hakami</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zohar&#x2010;Dayan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ben&#x2010;Zeev</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Grinspan</surname>
<given-names>Z</given-names>
</string-name>, et&#xA0;al. <article-title>Lisdexamfetamine therapy in paroxysmal non&#x2010;kinesigenic dyskinesia associated with the KCNMA1&#x2010;N999S mutation</article-title>. <source>Mov Disord Clin Pract</source>. <year>2022</year>;<volume>9</volume>(<issue>2</issue>):<fpage>229</fpage>&#x2013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">35141357</pub-id>
</mixed-citation>
      </ref>
      <ref id="epi412934-bib-0100">
        <label>100</label>
        <mixed-citation publication-type="journal" id="epi412934-cit-0100">
<string-name>
<surname>Leo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Citraro</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Constanti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>De Sarro</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Russo</surname>
<given-names>E</given-names>
</string-name>. <article-title>Are big potassium&#x2010;type Ca2+&#x2212;activated potassium channels a viable target for the treatment of epilepsy?</article-title>
<source>Expert Opin Ther Targets</source>. <year>2015</year>;<volume>19</volume>(<issue>7</issue>):<fpage>911</fpage>&#x2013;<lpage>926</lpage>.<pub-id pub-id-type="pmid">25840593</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>